





Assessing prognosis for early breast cancer: clinical
versus genetic profiles
GN Hortobagyi
Department of Breast Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA
Breast Cancer Research 2007, 9(Suppl 1):S1 (doi: 10.1186/bcr1684)
Since the introduction of systemic adjuvant chemotherapy (ACT) and
endocrine therapy in the early 1970s, the determination of risk of
recurrence and death from breast cancer became a critical piece of
information in the selection of the optimal postoperative treatment
strategy. Classical histopathological prognostic factors included tumor
size, regional lymph node metastases and number of axillary nodes
involved, tumor grade, presence of lymphovascular invasion, and, more
recently, estrogen receptor (ER) and progesterone receptor status,
measurement of proliferative activity (S-phase fraction, mitotic index,
Ki-67), and HER2 overexpression/amplification. As isolated factors,
they have limited predictive ability in the case of individual patients. For
that reason, prognostic indices were developed. The most successful
is Adjuvant!Online, an online nomogram developed by Peter Ravdin.
This nomogram incorporates tumor size, axillary nodal status, tumor
grade, ER status, age and comorbidity. The nomogram will provide an
assessment of recurrence and mortality rates at 10 years, including
deaths due to comorbid conditions. In addition, the nomogram also
calculates relative and absolute benefit from various adjuvant inter-
ventions: tamoxifen, aromatase inhibitors, and first-generation, second-
generation and third-generation ACT regimens. The prognostic and
predictive value of this nomogram has been externally validated, with a
margin of error ≤1%. Over the past decade, high-throughput
technologies have been developed based on gene expression profiling.
These include between two and a couple of hundred genes, and have
the ability to separate patients with excellent outcomes from those with
higher risk. One of these prognostic profiles has been externally
validated and is currently undergoing testing for clinical utility in a large,
multicenter, prospective randomized trial (MINDACT). Another
approach was based on prospectively identifying a set of genes from
the literature and from the results of gene expression profiling.
Mathematical modeling then led to the selection of 16 genes related to
cell proliferation, ER-driven genes, HER2 and proteases, as well as five
‘housekeeping’ genes (OncotypeDx). This assay is based on RT-PCR,
is reproducible and applicable to archival, paraffin-embedded material,
and has been shown to predict prognosis in patients with lymph-node-
negative, ER-positive primary breast cancer. Further testing indicated
that the assay might also predict sensitivity to tamoxifen, or first-
generation adjuvant chemotherapy. This assay is also under evaluation
for clinical utility in a large, multicenter, prospective randomized trial
(TailoRx). Whether these multigene predictors of prognosis will have
greater utility than Adjuvant!Online remains to be determined. In the
meantime, exploratory analyses are ongoing to identify reliable
predictors of response to individual drugs and modern combination
drug regimens. These are expected to lead to individualized selection
of treatment, or personalized medicine.
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Minimal residual disease (MRD) (that is, isolated tumor cells (ITC) in
bone marrow) may be the source of potentially fatal overt distant
metastases in solid tumors even years after primary treatment. MRD
can be detected by immunohistochemical methods using antibodies
directed against cytokeratins, cell-surface markers, or molecular, PCR-
based techniques. Among solid tumors, the clinical relevance of MRD
has been most extensively studied in breast cancer patients. Recently,
the highest level of evidence for the prognostic impact of MRD in
primary breast cancer was reached by a pooled analysis comprising
more than 4,000 patients, showing poor outcome in patients with MRD
at primary therapy. Yet, clinical application of MRD detection is
hampered by the lack of a standardized detection assay. Moreover,
clinical trial results demonstrating the benefit of a therapeutic
interference derived from bone marrow status are still missing. Recent
results suggest that, in addition to its prognostic impact, MRD can be
used for therapy monitoring or as a potential therapeutic target after
phenotyping of the tumor cells. Persisting MRD after primary treatment
may lead to an indication for extended adjuvant therapy.
In a pooled analysis, bone marrow aspirates of 726 patients from
academic breast cancer units in Oslo (n = 356), Munich (n = 228) and
Tuebingen (n = 142) were analyzed during recurrence-free follow-up at
a mean interval of 31.7 months after primary diagnosis of breast cancer
pT1-4, pN0-3 pM0. Persistent ITC were detected in 15.4% of the
patients (n = 112). The Kaplan–Meier estimate for mean distant
relapse-free survival estimate was 163.6 months in patients with
negative bone marrow status and 105.2 months in patients with
positive bone marrow status. Patients without evidence of persistent
ITC had a significantly longer overall survival (165.6 months), than
patients with positive bone marrow status (103.3 months, P < 0.0001).
In multivariate Cox regression analysis, allowing for bone marrow
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status, tumor size, nodal status and histopathological grading, ITC was
of independent prognostic significance for subsequent reduced breast
cancer specific survival (RR 6.3, 95% CI 2.3–17.6, P < 0.0001), next
to nodal status at time of primary diagnosis (RR 2.9, 95% CI 1.8–4.7).
Given these inspiring results on ITC in bone marrow, several trials
currently analyze the prognostic relevance of circulating tumor cells
(CTCs) in peripheral blood in the adjuvant setting. In Germany, for
example, CTCs in peripheral blood of breast cancer patients at primary
diagnosis and during adjuvant chemotherapy as well as endocrine and
bisphosphonate treatment within the SUCCESS Trial (n = 3,658
patients) are currently analyzed. In this study, the CellSearchSystem
(Veridex, Warren, USA) is used for isolation and enumeration of CTCs
from 23 ml peripheral blood. Briefly, after immunomagnetic enrichment
with an anti-Epcam antibody, cells were labelled with anticytokeratin
(8,18,19) and anti-CD45 antibodies to distinguish epithelial cells and
leukocytes. In an interim analysis, 456 breast cancer patients at the
time of primary diagnosis before the start of systemic adjuvant
treatment were analyzed. In this patient group, 28% of patients
(n = 129) presented with ≥1 CTC in peripheral blood. In patients with
the detection of CTCs, the mean number of cells was four (range
1–166). In 19 healthy individuals we found one CTC in the blood of
two patients. The presence of CTCs did not correlate with tumor size
(P = 0.18), presence of lymph node metastases (P = 0.09), histopatho-
logical grading (P = 0.56), hormone receptor status (P = 0.49) or
Her2/neu status of the primary tumor (P = 0.33).
Persisting MRD after primary treatment may lead to an indication for
extended adjuvant therapy. Until clinical consequences of MRD
detection in solid tumors and particularly in breast cancer have been
validated, however, the detection of isolated tumor cells in bone
marrow should be performed mainly in clinical trials.
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The detection of microscopic disease is associated with prognostic
implications in primary breast cancer [1]. In metastatic breast cancer
(MBC), reliable detection of circulating tumor cells (CTCs) has been
obtained using immunomagnetic separation and subsequent analysis
by the CellSpotter™ analyzer (Veridex LLC, a Johnson & Johnson
company, Warren, NJ, USA) [2,3]. This technology is becoming a
standard tool for the ‘real-time’ assessment of prognosis and response
to treatment [4,5]. The detection of CTCs in patients with MBC about
to start a new line of treatment has been shown to predict progression-
free survival and overall survival and treatment benefit. The prognostic
value was independent of the line of therapy (for example, first line
versus second line or more) [2,3]. Moreover, in multivariate analysis
CTCs demonstrated superior value compared with the site of meta-
stasis (for example, visceral versus soft tissue/bone), type of therapy,
and length of time to recurrence after definitive primary surgery.
Furthermore, the prognostic value of CTCs has been shown to be
superior to standard tumor markers (for example, Ca27-29), tumor
burden and phenotype of disease [6]. We have recently focused on
determining the feasibility of the genotypic characterization of CTCs
and correlating with the expression of similar genes in primary or
metastatic lesions [7].
Increases in the number of circulating endothelial cells (CECs) and
progenitors (CEPs) have been reported in various pathological
conditions including cancer [8,9]. At the clinical level, evidence is
emerging that CEC kinetics and viability might correlate with clinical
outcomes in cancer patients who undergo anti-angiogenic treatment
[10]. The CellSpotter™ analyzer is also being investigated for measure-
ment and characterization of CEC [11]. Therefore, CEC and CEP
measurement has potential as a surrogate marker for monitoring anti-
angiogenic treatment and drug activity, and could help to determine the
optimal biological dose of anti-angiogenic drugs, which are being used
with increasing frequency in medical oncology.
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Tumor factors that can predict prognosis and response to specific
therapies (for example, chemotherapy regimens) are of great potential
benefit for tailored treatment of patients with invasive breast cancer.
We have previously defined a gene expression profile of 70 genes that
is predictive for a short interval to distant metastases (< 5 years) in
lymph node negative (LN0) patients [1]. We have subsequently
validated the prognostic value of this 70-gene profile in a cohort of 295
stage I and II breast cancer patients younger than 53 years of age [2].
To test whether gene expression profiling can be used in clinical
practice, we have performed a study in 16 hospitals in The Nether-
lands. Female patients younger than 61 years presenting with primary
operable cT1-2N0M0 breast carcinoma were eligible and entered into
this prospective feasibility study. Fresh tumor samples in a standard-
ized fashion were collected within 1–3 hours of primary surgery and
sent in RNAlater® to the Netherlands Cancer Institute. The 70-gene
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signature (genomic profile) was obtained in node-negative patients with
a representative tumor sample; node-positive patients were excluded.
Between 2004 and 2006, 812 patients were enrolled and 427 (53%)
genomic profiles were obtained. The remaining 385 (47%) patients
were excluded mainly because of node-positive disease (22%). The
logistics of obtaining fresh-frozen material from the tumor has gone very
well in each of the participating hospitals. Approximately 50% of the
tumors were shown to have a good prognosis signature.
Another area of research is to identify gene expression signatures
associated with the response to chemotherapy. Within a single-
institution prospective phase II trial, patients with locally advanced
breast cancer received six courses of either doxorubicin-cyclo-
phosphamide (AC) (n = 25) or doxorubicin-docetaxel (AD) (n = 24)
containing neoadjuvant chemotherapy. Gene expression profiles were
generated from core needle biopsies obtained before treatment and
correlated with the response of the primary tumor to the chemotherapy
administered [3]. Additionally, pretreatment gene expression profiles
were compared with those in tumors remaining after chemotherapy
(n = 15).
Eleven (22%) of the 49 patients showed a (near) pathological complete
remission of the primary tumor after treatment. No gene expression
pattern correlating with response could be identified for all patients as
well as for the AC-treated or AD-treated group separately. The
comparison of the pretreatment biopsy and the tumor excised after
chemotherapy revealed differences in gene expression in those tumors
that showed a partial remission but not in tumors that did not respond
to chemotherapy.
No gene expression profile predicting the response of primary breast
carcinomas to AC-based or AD-based neoadjuvant chemotherapy
could be detected in this study. We are currently expanding the series
of patients in this neoadjuvant chemotherapy study.
We conclude that gene expression profiling is a method that has
greatly accelerated the identification of prognostic and predictive
factors in breast cancer and will lead to novel diagnostic tests that can
be reliably implicated in clinical practice.
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Many single-gene molecular markers have been evaluated as
predictors of response to specific regimens. However, no reliable and
routinely used molecular chemotherapy response predictors exist
today. Molecular markers of proliferative activity remain nonspecific
predictors of chemotherapy sensitivity in general. Multidrug-resistance
transport proteins, p53 gene mutations, and defects in apoptotic
pathways remain highly controversial as predictors of response or
resistance to particular drugs. To date, the strongest (although still
indirect) evidence supporting a molecular predictor of response to a
particular regimen comes from a retrospective subset analysis of a
variety of studies that showed a link between topoisomerase II
amplification and increased sensitivity to anthracyclines. However, the
best methodology for determining amplification of topoisomerase II and
the appropriate cut-off value to distinguish between individuals with
and without amplification have not been established.
Several small studies provided ‘proof-of-principle’ that the gene
expression profile of cancers that are highly sensitive to chemotherapy
is different from that of tumors resistant to treatment. Table 1 (overleaf)
presents a summary of the current literature. The most exciting
possibility implicit to gene expression profiling-based diagnostic tests
is that multiple predictors could be applied to a single data set. It is
currently technically feasible to perform gene expression profiling on a
single biopsy and assess prognosis using a 76-gene, or 70-gene
signature, determine the ER and HER-2 status by measuring receptor
mRNA levels, predict endocrine sensitivity among the ER-positive
patients and estimate the probability of response chemotherapy.
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Patient 
Reference characteristics Treatment Results
Chang et al. [1] 24 (discovery) and 4 cycles docetaxel 92 differentially expressed genes (P < 0.001)
6 (validation) every 3 weeks LOOCV results in training: predictive accuracy of 88% (95% CI, 68–97%), PPV 
patients. with LABC of 92%, NPV of 83%, sensitivity of 85% (95% CI, 55–98%), specificity of 91% 
(95% CI, 59–100%)
Independent validation: all six patients with sensitive tumors correctly identified
Ayers et al. [2] 24 (discovery) and 3 or 12 cycles paclitaxel and No single gene sufficiently associated with pCR to serve as single valid marker
12 (validation) 4 cycles of FAC (T/FAC) 74-gene predictor for response to chemotherapy
patients with breast – Predictive accuracy of 78% (95% CI, 52–94%), PPV of 100% 
cancer (95% CI, 29–100%), NPV of 73% (95% CI, 45–92%), sensitivity of 43% 
(95% CI, 10–82%), specificity of 100% (95% CI, 72–100%)
Iwao-Koizumi 44 (discovery) and 4 cycles of docetaxel 85-gene-predictor of pCR with:
et al. [3] 26 (validation) – Predictive accuracy of 80.7% (95% CI, 63.5–92.5%), PPV of 73.3% 
patients. with (95% CI, 49.5–90.3%), NPV of 90.9% (95% CI, 65.9–99.4%), sensitivity of 
stage II/IV breast cancer 91.7% (95% CI, 68.1–99.5%), specificity of 71.4% (95% CI, 46.7–89.5%)
Hannemann et al. [4] 48 patients with 6 cycles of doxorubicin/docetaxel No differentially expressed genes identified, no possible multigene predictor 
LABC (AD, n = 24) or doxorubicin/ developed
cyclophosphamide (AC, n = 24) Patient samples did not cluster distinctly for pCR/near pCR compared with RD in 
hierarchical clustering
Gianni et al. [5] 89 (INT-Milan) and 3 cycles of doxorubicin/paclitaxel, 86 genes correlating with pCR (P < 0.05) forming three clusters
82 (MDACC) 12 cycles of weekly paclitaxel – ER gene cluster
patients with LABC – Proliferation gene cluster
– Immune-related gene cluster
RS correlated with pCR in INT-Milan patients
86-gene model developed on INT-Milan patients validated on MDACC samples 
Folgueira et al. [6] (1) 38 (discovery), (1) 25 (3.8%) differentially expressed transcripts between responders and 
13 (validation) non-responders, three-gene classifier could not be validated
(2) 31 (discovery), (2) Three-gene classifier successfully developed and validated both by LOOCV 
13 (validation) and in an independent validation set
Dressman et al. [7] 37 patients with Liposomal doxorubicin x 4/paclitaxel (a) 22-gene signature characterizing IBC identified and validated by LOOVC
stage IIB/III breast combined with local whole breast (b) 18-gene signature characterizing IBC identified and validated by LOOVC
cancer hyperthermia (c) No gene signature predicting clinical response could be identified
Thuerigen et al. [8] 52 (discovery/ GEsDoc (gemcitabine, epirubicin 512-gene-signature predictive of pCR: predictive accuracy of 88% 
GEsDoc), 48 every 2 weeks x 5 followed by (95% CI, 75–95%), PPV of 64% (95% CI, 39–81%), NPV of 95% 
(validation/GEDoc) docetaxel every 2 weeks x 2), (95% CI, 82–99%), sensitivity of 78% (95% CI, 40–97%), specificity of 90% 
patients with GEDoc (gemcitabine, epirubicin, (95% CI, 76–97%)
T2-4N0-2M0 docetaxel every 3weeks)
breast cancer
Park et al. [9] 21 patients with 4 cycles of FEC every 3 weeks 11 differentially expressed ABC transporters
stage II/III breast followed by 12 cycles of weekly Multigene predictor model with the ABC transporters differentially expressed 
cancer paclitaxel between the two classes (P < 0.003) with predictive of pCR with: 
– Predictive accuracy of 92.8% (95% CI, 88.0–97.4%), PPV of 93.2% 
(95% CI, 85.2–100%), NPV of 93.6% (95% CI, 87.8–99.4%), sensitivity of 
88.1% (95% CI, 76.8–99.4%), specificity of 95.9% (95% CI, 87.8–100%)
Cleator et al. [10] 40 patients with 6 cycles doxorubicin/ 253 differentially expressed genes;
primary breast cyclophosphamide (AC) – 75 genes overexpressed in resistant tumors (that is, transcription, differentiation, 
cancer signal transduction, amino acid metabolism)
– 178 genes overexpressed in sensitive tumors (that is, cell cycle, survival, stress 
response, and estrogen-regulated genes)
Hess et al. [11] 82 (discovery), 3 or 12 cycles paclitaxel and 30-gene predictor identified and validated by fivefold cross-validation, permutation 
51 (validation) 4 cycles of FAC (T/FAC) testing and application to an independent data set:
– Predictive accuracy of 76% (95% CI, 62–87%), PPV of 52% 
(95% CI, 31–73%), NPV of 96% (95% CI, 82–100%), sensitivity of 92% 
(95% CI, 64–100%), specificity of 71% (95% CI, 54–85%)
Mina et al. [12] 45 patients with 3 cycles doxorubicin every 22 of 274 candidate genes correlated with pCR (P < 0.05) forming three large 
stage II/III breast 2 weeks and 6 cycles docetaxel clusters: angiogenesis-related genes, proliferation-related genes, invasion-related 
cancer weekly x 6 genes, no correlation between RS and pCR, 24/274 genes correlated with 
inflammatory phenotype
ABC transporter, ATP binding cassette transporter; discovery, development/training set; FAC, 5-fluorouracil, doxorubicine, cyclophosphamide; FEC, 5-fluorouracil,
epirubicin, cyclophosphamide; IBC, inflammatory breast cancer; LABC, locally advanced breast cancer; LOOCV, leave-one-out cross-validation; NPV, negative predictive
value; pCR, pathological complete response; PPV, positive predictive value; RD, residual disease; RS, recurrence score (Oncotype DX©); validation, validation set.
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New technologies have raised the issue of their application as a
replacement for or in addition to screen-film mammography in screen-
ing of women at normal risk and elevated risk of breast cancer.
Digital mammography images the breast using the identical information
obtained in screen-film mammography. The image is processed, stored
and displayed electronically. This conveys several advantages over film
techniques, but the approval of digital mammography by the US Food
and Drug Administration has been based on comparable ability to
detect cancer, not any diagnostic advantage.
Four prospective studies comparing digital and film mammography on
the same patients have shown that for population-based screening
there is no advantage for digital over film. The last and largest of these
studies [1] initially reported an advantage for several subgroups of
women for digital screening. Later analysis of data from this study,
however, concluded that only women with dense breasts may benefit
and that screening of entire populations with digital mammography is
excessively costly and not beneficial.
Analysis of MR as a screening tool has been directed at women with
greatly elevated lifetime risk of developing breast cancer. The ability of
MR to detect a large percentage of cancers in these women earlier
than mammography, sonography or physical examination and at a stage
at which they should be curable has been clearly demonstrated. This
has lead the American Cancer Society, along with others, to
recommend the use of MR to annually screen women with at least a
20% lifetime risk of developing breast cancer starting at age 25 years.
Those at less risk were not included due to lack of supporting data and
concern over excessive biopsies in those women.
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Several unique surgical issues arise in the management of patients
who are candidates for neoadjuvant systemic therapy. These involve
the original diagnostic assessment of the extent of disease in the
breast and axilla, the preoperative planning, and ultimately the surgical
management of the primary breast tumor and that of axillary lymph
nodes. Careful consideration of these issues is crucial in order to
maximize local control of the disease, while minimizing the extent of the
required surgical resection and the ensuing surgical morbidity.
Adequate diagnostic assessment with core needle biopsy before the
initiation of neoadjuvant systemic therapy ensures the presence of
invasive carcinoma and provides adequate material for routine bio-
marker evaluation (such as ER, PR and HER-2 neu), while minimally
disturbing the primary breast tumor. Consideration should also be
given in assessing the status of axillary nodes by minimally invasive
techniques such as ultrasound of the axilla and fine needle aspiration of
suspicious nodes. Optimal preoperative planning aims at accurately
determining the patterns of primary tumor shrinkage and the amount
and location of any residual disease in the breast.
Surgical treatment after neoadjuvant systemic therapy focuses on the
management of the primary breast tumor and that of axillary lymph
nodes. Regarding the primary breast tumor, several studies have
shown that neoadjuvant systemic therapy converts a proportion of
mastectomy candidates to candidates for breast-conserving surgery.
Neoadjuvant systemic therapy can also decrease the amount of breast
tissue that needs to be removed at lumpectomy even in patients who
are lumpectomy candidates at presentation.
Neoadjuvant systemic therapy (primarily neoadjuvant chemotherapy)
downstages axillary lymph nodes in up to 30–40% of the patients.
Although this observation was of little clinical significance when axillary
node dissection was the sole method for staging the axilla, the
development and validation of sentinel lymph node biopsy has provided
an additional potential advantage for neoadjuvant chemotherapy; that
is, the possibility of decreasing the extent and morbidity of axillary
surgery. This approach is, naturally, predicated on the premise that
sentinel node biopsy is feasible and accurate following neoadjuvant
chemotherapy. Until recently, only small, single-institution studies have
examined the efficacy of lymphatic mapping and the accuracy of
sentinel node biopsy after neoadjuvant chemotherapy with significant
variability in the rate of sentinel node identification and in the rate of
false negative sentinel node [1]. When these studies are examined
collectively [1,2] or when larger, multicenter data sets are analyzed [3],
however, sentinel node biopsy after neoadjuvant chemotherapy
appears to have similar performance characteristics to those of sentinel
node biopsy before systemic therapy [4-6].
Some have proposed that candidates for neoadjuvant systemic therapy
should have a sentinel node biopsy before, rather than after,
neoadjuvant systemic therapy so that information on the status of the
axillary nodes is obtained without the potential confounding effects of
systemic treatment, and sentinel node-negative patients can avoid
axillary dissection [7-9]. Although this approach may be useful in
patients who will not need systemic therapy (that is, chemotherapy) if
the sentinel node is negative, it is not generally useful for the majority of
candidates for neoadjuvant systemic therapy, for whom little – if
anything – is to be gained by knowing the pathologic nodal status
upfront. In addition, this approach commits patients to two surgical
procedures and does not take advantage of the down-staging effect of
neoadjuvant chemotherapy on the axillary nodes.
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Background Approximately 12,000 women with primary breast cancer
present with stage IV disease annually in the United States. The present
treatment paradigm is that systemic therapy is the standard of care and
surgical therapy for the primary tumor is provided only to palliate symptoms.
Methods We have examined the impact of local therapy on survival in
patients presenting with stage IV breast cancer at initial diagnosis,
reporting to the National Cancer Database (NCDB) between 1990 and
1993. In a subsequent study, we reviewed the medical records of
women presenting with stage IV breast cancer to Northwestern
Memorial Hospital (NMH) over the 10-year period 1995–2005. Cox
regression models and logistic regression was used to estimate
adjusted overall survival in both studies, and the time to first
progression (TTFP) and chest wall status in the NMH population.
Results A total of 16,024 patients with stage IV disease were
identified in the NCDB over 4 years, of whom 42.8% received only
diagnostic or palliative procedures, and 57.2% underwent partial or
total mastectomy. A multivariate proportional hazards model identified
the number of metastatic sites, the type of metastatic burden, and the
extent of resection of the primary tumor as significant independent
prognostic covariates. Women treated with surgical resection with free
margins, when compared with those not surgically treated, had
superior prognosis, with a hazard ratio of 0.61 (95% CI 0.58–0.65). In
the NMH study, we identified 114 women; 48 (42%) underwent
resection of the primary tumor. Local control of the chest wall was
maintained in 36/48 (75%) of the surgical group, versus 31/66 (47%)
patients without surgical therapy (P = 0.002). TTFP was prolonged in
the surgical group, adjusted HR 0.639 (P = 0.03). The HR for overall
survival in the surgical group was 0.724 (P = 0.160). Notably, in
women with controlled chest walls we observed an overall survival
benefit with a HR of 0.418 (P < 0.0002).
Conclusion Recent retrospective studies suggest that surgical
resection of the primary tumor in women who also have distant disease
may be beneficial [1-3]. These are remarkably consistent in the
magnitude of the survival advantage, with a hazard ratio of about 0.6
when surgical intervention is used. There is a paucity of data supporting
the assumption that surgical resection will maintain a disease-free chest
wall. A study of women with in-breast recurrence of breast cancer and
synchronous distant metastases found that women undergoing
resection were more likely to avoid uncontrolled chest-wall disease and
to survive longer [4]. Our study at NMH (the largest reported to date
examining this issue) finds that maintenance of a disease-free chest wall
is associated with improved survival. This further emphasizes the need
for prospective randomized trials to establish the role of local therapy in
the setting of metastatic breast cancer.
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With numerous advances in the field of plastic surgery, breast recon-
struction is available today to almost any woman undergoing surgery
for breast cancer. Several methods can be used for restoration of the
breast either at the same time as breast cancer surgery (immediate
reconstruction) or months or even years later, at the patient’s discretion
(delayed reconstruction). The skin sparing approach to mastectomy,
originated in the early 1990s, has especially facilitated immediate
reconstruction of the breast and resulted in a high standard of
cosmetic outcomes. In general, the reconstructive options include
using autologous soft tissues from the patient’s donor areas, such as
the abdomen, hips, back, or buttock, or using a prosthetic implant to
create a new breast mound. For well over a decade now, skin-sparing
mastectomy and immediate reconstruction has offered the compelling
advantages of both superior cosmetic appearance of the reconstructed
breast as well as favorable psychological and economic benefits [1].
For many years in the past there was the misconception that breast
reconstruction must be delayed for several years after mastectomy
because reconstruction might prevent or delay detection of local
recurrence. Hence, a large population of women has sought and
presently still seeks to undergo delayed postmastectomy recon-
struction months to years later. The outcomes of these reconstructions
are good to excellent but the cosmetic outcome is always somewhat
inferior to the results obtainable by immediate reconstruction because
of the loss of the breast skin envelope after mastectomy and the need
to replace so much of the chest wall skin. In regard to the all-important
question of local recurrence, several longer term follow-up studies at
the MD Anderson Cancer Center actually indicate a lower incidence of
local recurrence after immediate reconstruction.
Current comparative statistics for the numbers of patients undergoing
immediate as well as delayed reconstruction from 2002–2006 are
presented in Table 1. Since 2002, the MD Anderson Plastic Surgery
Department has seen a progressively increasing demand of early
breast cancer patients for implant-based reconstructions performed on
an immediate basis. The opposite trend of a preference of autologous
tissue reconstructions is apparent for delayed reconstructions.
The controversy today is that we continue to undergo an important
evolution in our approach to breast reconstruction because of the
identified advantage of the addition of postmastectomy radiation
therapy to mastectomy and chemotherapy. The inability to determine
which patients will require postmastectomy radiation therapy,
especially which patients with early-stage breast cancer, has increased
the complexity of planning for immediate breast reconstruction. There
are two potential problems with performing an immediate breast
reconstruction in a patient who will require postmastectomy radiation
therapy. One problem is that postmastectomy radiation therapy can
adversely affect the aesthetic outcome of an immediate breast
reconstruction [1-3]. The other potential problem is that an immediate
breast reconstruction can interfere with the delivery of postmastectomy
radiation therapy. Because radiation therapy is one of the most
important considerations affecting the timing and technique of breast
reconstruction, plastic surgeons and radiation oncologists must work
together to maintain an appropriate balance between minimizing the
risk of recurrence and providing the best possible aesthetic outcome.
Our experience at the MD Anderson Cancer Center and many of the
other experiences reported in the literature indicate that breast
reconstruction should probably be delayed in patients who are known
preoperatively to require postmastectomy radiation therapy [2,4].
Considering, then, our evolving approach for early breast cancer
patients who want immediate breast reconstruction but are at higher
risk for postmastectomy radiation therapy and likely delayed recon-
struction, our updated ‘delayed-immediate’ [5] reconstruction
experience between May 2002 and November 2006 includes 42
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patients who were considered preoperatively to be at an increased risk
of requiring postmastectomy radiation therapy (PMRT) and underwent
delayed-immediate breast reconstruction at the MD Anderson Cancer
Center. After review of the permanent pathology, 62% (26 of 42
patients) of patients did not require PMRT and, because of the preserved
breast envelope, could go ahead with essentially an immediate
reconstruction. The remaining 38% (16 of 42 patients) did require
PMRT, but selected patients are being managed on a similar IRB
reconstruction protocol that will allow a ‘skin-preserving’ delayed
reconstruction following completion of the PMRT. Fifteen of these 16
patients (94%) were evaluated as having uncompromised radiation
delivery. Cosmetic results of this approach are very promising and
compare favorably with immediate reconstruction in the short-term
follow-up to date. Complication rates with delayed-immediate
reconstruction are considered quite acceptable and included: stage I
(three of 42 patients, 7%), stage II (four of 26 patients, 15%), skin-
preserving delayed reconstruction (one of 13 patients, 7%), and
expander loss (surgery-related, 2%; PMRT-related, 6%). Only 2% (one
of 42 patients) of the patients developed a recurrence of breast cancer
after an average follow-up of 24 months.
Breast reconstruction plays an important role in the multidisciplinary,
comprehensive care of the breast cancer patient. Advances in
techniques have allowed immediate reconstruction to minimize
incisional scars on the breast and improve overall breast contour, shape,
and appearance. The improved aesthetic outcomes over delayed
reconstruction, achieved also by the skin-preserving ‘delayed- immediate’
approach for early breast cancer patients at risk for radiation therapy
and similarly for selected patients actually undergoing PMRT, has
convinced many breast cancer patients to view mastectomy with
reconstruction as a viable and positive treatment choice. Those patients
who are candidates for and who will undergo delayed reconstruction,
either because of the planned need for adjuvant radiotherapy or
because of poorly controlled comorbidities that must be stabilized
before a reconstruction can be undertaken, can still anticipate an
excellent cosmetic outcome with a record of high patient satisfaction.
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Background Under certain conditions, the nipple sparing mastectomy
can be proposed for the treatment of breast cancer when the
mastectomy remains indicated. The nipple areola complex (NAC)
preservation improves the quality of life, reducing the feeling of
mutilation. The main argument against the procedure is the lack of
radical resection of the retroareolar ductal system. A novel
radiosurgical treatment combining subcutaneous mastectomy with
intraoperative radiotherapy is proposed.
Methods Seven hundred and seventy-three nipple sparing mastec-
tomies have been performed since March 2002, for invasive carcinoma
in 63% and for in situ carcinoma in 37%. Clinical complications,
aesthetic results, and oncological and psychological results were
recorded.
Results The NAC necrosed totally in 26 cases (3.3%) and partially in
49 cases (6.3%), and was removed in 36 cases (4.6%). Thirteen
infections (1.6%) were observed and 32 (4.14%) prostheses removed.
The median rating of the patients for global cosmetic results on a 0
(worst) to 10 (excellent) scale was 8. The surgeon in charge of the
follow-up has given the same rating. A radio dystrophy was observed
on the areola in 5.1% of the patients. The sensitivity of the NAC
recovered slowly and partially in only 30% of the cases. Twelve local
recurrences (1.5%) occurred in an average follow-up period of 18
months (range 1–61 months). Most recurrences were located far from
the nipple areola site, outside the radiated field. Two recurrences were
Paget disease associated with an in situ carcinoma. Overall, we
observed 23 metastases and three deaths. Sixty-eight per cent of
patients were satisfied with their reconstructed breast and 97% were
satisfied with having preserved the NAC.
Introduction
Conservative treatment is now well accepted for a majority of breast
cancers and is performed in around 70–80% of cases [1]. However,
mastectomy remains indicated in at least 20% of patients. An important
improvement resulted from the skin-sparing mastectomy technique,
validated by several publications [2-11]. The preservation of the skin
envelope has favoured the quality of the breast reconstruction, and
breast reconstructive surgery has made important progress, providing
more natural shape. However, despite the reconstruction, patients
often deplore a feeling of mutilation. The nipple areola complex (NAC)
Available online http://breast-cancer-research.com/supplements/9/S1
Table 1 (abstract S9)
Immediate versus delayed breast reconstruction, 2002–2006, MD Anderson Cancer Center
Number of immediate reconstructions                 Number of delayed reconstructions
Total number of Number of 
Year Implant Patient’s own tissue Implant Patient’s own tissue reconstructions mastectomies
2002 167 153 43 55 418 418
2003 186 176 53 68 483 482
2004 256 158 45 84 543 541
2005 239 164 48 75 526 523
2006 313 234 39 98 684 683
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appears an identity mark of the breast [12]. Several authors have
evaluated the risk of nipple areola involvement and investigated the
possibility of nipple areola preservation [13-18]. Focusing on such risk,
and the possible cancer recurrence in the breast tissue preserved
beneath the NAC for the blood supply, we proposed to combine the
subcutaneous mastectomy technique with intraoperative radiotherapy
with electrons (ELIOT), previously trialled in breast-conserving
treatment [19]. The preliminary results of the ‘nipple sparing mastec-
tomy’ (NSM) were published in 2003 [20]. Today, we report the results
of 773 NSMs performed at the European Institute of Oncology.
Materials and methods
From March 2002 to March 2007, 898 patients were invited to
undergo a NSM. The inclusion criteria were primary tumours located at
least 1 cm outside the areola margins, an absence of nipple retraction
or bloody discharge, and an absence of retro areola micro-
calcifications. Multifocality was not a cause for exclusion, provided that
all the tumour sites were distant from the areola. Invasive as well as in
situ carcinomas were included. Patients were excluded at the time of
the operation when the frozen examination of the retro areola tissue
had been positive for carcinoma: in these cases, ELIOT was not
delivered and the NAC was removed. Among the 898 cases, 98 were
excluded, mainly because of the positive extemporaneous examination
and in several cases because of the poor blood supply requiring the
NAC removal. Fifty-one candidates were excluded because no
radiotherapy was delivered, most often when the blood supply was
poor and the risk of necrosis very high. Finally, 749 patients underwent
a NSM, among whom 24 had a bilateral NSM.
The mean patient age was 46 years (range 20–73 years). Seventy-five
per cent of the patients have a mean follow-up of 18 months (range
1–61 months).
The surgical technique has already been described [20]. Breast
reconstruction was achieved with a definitive prosthesis in 689 cases
(89%) and with an expander in 185 (24%). Only six patients underwent
a reconstruction with an autologous transverse rectus abdominis
myocutaneous and one with an autologous Latissimus dorsi.
Once the glandular tissue has been removed and the frozen section of
the retro areola tissue proved free of cancer, ELIOT was performed on
the NAC area. The ELIOT technique has already been described
[21-24]. In our technique, 16 Gy were delivered on the NAC in one
shot with lead and aluminium disk protection of the pectoralis muscle
and thoracic wall (see Figure 1). However, in 145 cases, the same
radiotherapy was postponed to the following day, due to technical
problems with the machine in the operating room.
Sensitivity, colour, radio dystrophy, position and symmetry, and global
evaluation by the surgeon and the patient, were rated according to a
scale (0–10), 10 indicating the best results. (The results were rated
poor when rated from 0 to 3, fair from 5 to 6 and good or excellent
from 7 to 10.)
Local recurrences, distant metastases and death were also recorded.
A psychological study was conducted concomitantly. A detailed
questionnaire was sent to the patients 1 year after the operation to
evaluate the degree of satisfaction. The statistic analysis of psychological
results was performed with the chi-square test and exact Fisher test.
Results
NAC total necrosis was observed in 26 cases out of 773 NSMs
(3.3%). Partial necrosis was observed in 49 cases (6.3%). The NAC
was removed in 36 cases (4.6%). The definitive histology of the 773
NSMs was invasive carcinoma in 63% and in situ carcinoma in 37%. In
53 cases (6%), the definitive histology of the retro areola tissue
returned positive for carcinoma (invasive in 35 cases and in situ in 18
cases). Thirteen infections (1.6%) were observed in the immediate
postoperative period; 32 prostheses were removed (4.1%). A capsulo-
tomy has been required in 137 cases (17.7%).
Cosmetic results and sequelea were evaluated by the surgeon in
charge of the follow-up according to the scale previously mentioned.
The average evaluation of the sensitivity of the areola and the
periareolar area was 2/10. Thirty per cent of the patients recovered
some kind of sensitivity in several months. The colour of the areola was
judged 8/10. The radio dystrophy was absent in most cases: 9/10. A
radio dystrophy such as telangiectasia has been observed in 5.1% of
the cases. The symmetry of the breasts was evaluated well in most
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Figure 1 (abstract S10)
(a) The sterile collimator of the LINAC. (b) The gauze over the areola
allows a more homogeneous distribution of the dose to the nipple and
the areola. (c) Protective lead and aluminum disks. (d) Pectoralis major
muscle.
Figure 2 (abstract S10)
Case 1. (a) Preoperative drawing and result. (b) and (c) Final result with contralateral augmentation.
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cases: 7/10. The global result was rated by the patient as 8/10 and
also as 8/10 by the surgeon (see cases 1–3, Figures 2–4).
Cancer results
Despite the frozen section performed underneath the NAC to eliminate
the cases with positive results, the final histology of the retro areola
tissue was positive in 53 (6.8%) cases, among which 35 were invasive
carcinomas (66%). However, the NAC has been preserved in most
cases when the final examination returned positive, taking into account
the intraoperative radiotherapy to avoid recurrences. The secondary
removal was due to local necrosis. Twelve local recurrences were
observed. Two were located on the NAC and the 10 others at a
distance from the radiated area, usually in the same area of the tumour
location. Both recurrences on the NAC were a DCIS associated with a
Paget disease on the nipple. No recurrence on the NAC was observed
in the group of patients with persistent positive histology.
Twenty-three cases of distant metastases and three deaths were
observed in our series.
The psychological study was completed for 159 patients who had at
least 1 year follow-up and who answered our questionnaire. Ninety-
seven per cent of the patients interviewed declare being very satisfied
with the appearance of the breast after the NSM. No patient regretted
having undergone reconstructive surgery, and 91.5% agreed with the
mutilation being decreased by having preserved the NAC. Similarly,
93% of women responded that conserving the nipple aided in facing
illness, and only 1.6% expressed a total dissatisfaction.
Discussion
Our study on 773 skin-sparing mastectomies performed at the
European Institute of Oncology confirms the feasibility of the
procedure, with a majority of good results after the preservation of the
NAC. However, a partial or total NAC necrosis due to insufficient blood
supply was observed in 9.7% of the cases. Moreover, 6.6% of the final
retro areola histology return positive while it was observed negative at
the frozen section. Such results could be improved with a better
selection of the NSM, if we cancel the cases requiring an extensive
retro areola tissue removal and if we change the surgical indications of
the reconstruction in cases of large breast, more often using
autologous tissue reconstruction. Concerning the retro areola free
margins, we should verify with more accuracy the clinical proximity
between the tumour and the NAC.
A partial or global return of the NAC sensitivity was present in only
30% of the patients. As expected, the return is incomplete and takes
months to happen [25]. The risk of radio dystrophy is low with such
intraoperative radiotherapy at the level of 16 Gy. Seven per cent of the
patients had a severe or moderate radio dystrophy, but a mild
pigmentation was observed in around one-third of the women with at
least 1 year follow-up.
Two in situ local recurrences were observed on the preserved NAC,
which is reassuring although the median follow-up is only 18 months. A
longer follow-up is required to prove the efficacy of the intraoperative
radiotherapy. The dose of ELIOT chosen to reduce the recurrence risk
could be questioned [20-24]. The single application of 16 Gy
corresponds to the classic fractioned radiotherapy of 45 Gy for tumour
cells and of 70–80 Gy for late responding normal tissue. This dose
should be sufficient to sterilise more than 90% of the residual cancer
cells, and to obtain an acceptable risk (less than 5%) of severe late
complications (necrosis). However, the percentage of patients with
positive persistent carcinoma behind the NAC in our series justifies
ELIOT, although other authors advocate the possibility of NAC
preservation without ELIOT [13,26-29].
Finally, the primary goal of the NSM is the psychological improvement
of patients requiring a mastectomy. The preliminary results of the
questionnaire report a high level of satisfaction and confirm the
psychological importance of NAC conservation.
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Case 2. (a) Right NSM. (b) Breast reconstruction with TRAM flap.
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Case 3. (a) Left nipple sparing mastectomy, right prophylactic
mastectomy. (b) Bilateral reconstruction with prosthesis.
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Over the past few years an increasing number of papers have appeared
in peer-reviewed journals detailing various partial breast irradiation (PBI)
approaches, utilizing high-precision external beam radiation therapy,
single-dose intraoperative radiation therapy or brachytherapy. The
concept of PBI has been associated with the use of accelerated
schedules of fractionation. More recently, several preliminary clinical
reports of retrospective series and the 5-year results of the only
randomized study from Budapest using brachytherapy have produced
significant discussion and confirmed the widespread interest toward
PBI. The comparison between the current standard with early data
coming from PBI techniques poses a dilemma as to when preliminary
results are sufficiently mature to consider a new treatment approach as
safe.
PBI allows reducing the radiation field to only the initially involved
quadrant of the breast and significantly shortens the duration of
radiation therapy. This may represent the possibility of overcoming
constraints such as accessibility to the radiation therapy centres, and
the socioeconomic impact on the working life and on the personal
habits of the patient. PBI seems to have a positive impact on patients’
quality of life. Another important advantage is the avoidance of
interactions with systemic therapy that may determine delays in the
initiation or in the carrying out of the conventional treatment.
These possible benefits must be balanced with the potential risk of
recurrence within the untreated tissue in the breast receiving PBI as
well as the unknown long-term cosmetic results with the accelerated
techniques. Significant practical considerations also include the choice
of technique, interstitial brachytherapy (high dose-rate versus low dose-
rate), balloon-based brachytherapy (MammoSite®), external beam (3D-
conformal versus intensity modulated radiation therapy), and intra-
operative irradiation (electrons versus low-energy X-ray device). The
choice of the technique has an impact on the schedules and dose-rate
that can be used, on the volume that can be irradiated and on the dose
homogeneity achievable.
Patient selection also remains uncertain, including questions regarding
age exclusions, applicability with various primary tumour sizes,
hystopathological features, the tumour-free margin and amount of
tumour near the margins, and negative (including micrometastasis) or
positive axillary lymph node status (up to three or more).
For this reason, data coming from the multicentric or unicentric large
phase III ongoing trials in the United States and Europe comparing
standard irradiation with the different PBI schedules and techniques will
hopefully support the movement of PBI into routine clinical practice.
Issues of patient selection, target volume definition, total dose,
fractionation, and the quality assurance programme should be addressed
and defined from analysing the results of such randomized trials.
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SYMPOSIUM III
Controversies in Clinical Practice (Part I)
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The increased risk of death from cancer in young women attests to its
aggressive nature and a greater likelihood of being oestrogen receptor
(ER)-negative. Approximately 60% of tumours are ER-positive, however,
and thus endocrine therapy is an important consideration in this group.
In some countries chemotherapy alone was used for many years until
the importance of the additional therapeutic effect of amenorrhea
became evident and later, after much scepticism, tamoxifen was shown
to be effective in this group of women. Sadly this rather staccato
history of treatment has left many questions concerning endocrine
therapy in young women unanswered. For example, there have been at
least nine studies that show ovarian suppression is equivalent for
disease-free and overall survival to chemotherapy, showing equivalent
therapeutic advantage. However, the correct design of their studies
should have included a third arm of chemotherapy and ovarian ablation
and some randomisation to investigate the role of additional tamoxifen.
New trials such as SOFT, TEXT and PROMISE will help answer the
question of optimal endocrine therapy ± chemotherapy in young
women and will also help decide whether aromatase inhibitors are
effective in the presence of ovarian suppression. Two further points are
important to consider. One is that chemotherapy used alone in very
young women with ER-positive disease is detrimental since they do not
have chemotherapy-induced amenorrhoea. Secondly, the value of
chemotherapy in strongly ER-positive disease is being increasingly
questioned.
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Unsupervised gene expression array profiling has provided biological
evidence for the heterogeneity of breast cancer through the identification
of intrinsic subtypes such as luminal A, luminal B, HER2+/ER– and the
basal-like subtype. The basal-like subtype is characterized by low
expression of both the ER and HER2 clusters of genes, so is typically
ER-negative, PR-negative, and HER2-negative on clinical testing; for this
reason, it is often referred to as ‘triple-negative’ breast cancer.
Basal-like breast cancer has some unique characteristics. It is the type of
breast cancer that BRCA1 mutation carriers generally develop, although
most basal-like breast cancers are sporadic. It comprises approximately
15% of all breast cancers, but is overrepresented among young African-
American women who develop breast cancer, in whom it comprises 39%.
Although it does not occur at higher stages than other breast cancer
subtypes, it is usually high grade and highly proliferative, which may
explain the poor prognosis associated with this subtype in several series.
Given the triple-negative status of basal-like breast cancer, it cannot be
treated with ER-targeted or HER2-targeted therapies, so is primarily
treated with chemotherapy. Fortunately, advances in adjuvant therapy
appear to benefit ER-negative breast cancer even more than ER-
positive breast cancer, and women with the basal-like subtype have
similarly benefited. In addition, in cohorts of breast cancer treated with
neoadjuvant chemotherapy, the pathologic complete response to
anthracycline/taxane-based therapy was significantly higher among
basal-like breast cancers than luminal breast cancers. The women with
pathologic complete response have good outcome; the poor prognosis
of basal-like breast cancer appears to relate to a particularly high risk of
early distant relapse among those that had residual disease. Among
the targeted agents for breast cancer, bevacizumab added to paclitaxel
in a randomized phase III trial appeared to have similar benefit in the
triple-negative subset as the other breast cancer phenotypes, suggest-
ing effectiveness in basal-like breast cancer. Current investigations into
other therapeutic options for this subtype include confirmation of
effectiveness of VEGF targeting, examination of EGFR-targeted
strategies, determining whether the association of basal-like breast
cancer with BRCA1 mutations means that this DNA repair pathway is
dysfunctional in all basal-like breast cancer, and determining whether
specific chemotherapy agents have greater or lesser efficacy in this
subtype. Future studies should also focus upon identifying whether
there are particular genetic or environmental risk factors for basal-like
breast cancer that differ from other subtypes, and whether there are
metastatic or predictive signatures that can be identified within the
basal-like subtype.
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Metastatic breast cancer patients represent a very heterogeneous
population and several factors are important for therapeutic decision:
patient characteristics including age, comorbidities, and performance
status, tumor biological characteristics, site and extension of metastatic
spread, prior adjuvant therapies and disease-free interval. In the past
years, adjuvant treatment has been rapidly changing as new cytotoxics,
new endocrine agents and targeted therapies are becoming the
mainstay of treatment [1]. For endocrine-sensitive breast cancer,
several large randomized trials have shown that third-generation
aromatase inhibitors, can reduce the risk of relapse of early breast
cancer in comparison with tamoxifen. Nowadays, aromatase inhibitors
administered up front, as a switch after 2–3 years of tamoxifen or as
extended treatment after 5 years of tamoxifen represent the standard
treatment in postmenopausal women. As anthracycline and taxanes are
the most active cytotoxic agents in breast cancer, anthracycline/taxane-
containing regimens are becoming the mainstay of adjuvant
chemotherapy. Finally, the growing understanding of the biology of
breast cancer cells led to identification of key molecular points that
represent possible therapeutic targets. Trastuzumab, the monoclonal
antibody against the HER-2 receptor, is approved for the treatment of
high-risk early breast cancer overexpressing HER-2 and represents the
standard treatment in these patients. With increasing use of very active
drugs in the adjuvant setting, there is a greater need for effective
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therapy at the time of relapse [2]. In endocrine-sensitive breast cancer,
sequencing data for anastrozole and tamoxifen have shown that
tamoxifen is likely to be effective after progression on anastrozole.
Moreover, in recent years Fulvestran, a selective ER downregulator
acting as a pure antiestrogen agent, has been developed. Tamoxifen,
Fulvestran or an aromatase inactivator are possible options after failure
of adjuvant aromatase inhibitors. At present, it is not possible to define
the optimal sequence of these endocrine agents. In endocrine-resistant
disease, a treatment-free interval (TFI) >12 months after adjuvant
chemotherapy has been shown to be an important factor for
determining sensitivity to drug rechallenge. If the tumor has been
exposed to an anthracycline and a taxane in adjuvant setting and the
TFI is >12 months, the re-treatment with the same agents may be an
option [3]. If the TFI is <12 months it is preferable to use a different
agent. Capecitabine, gemcitabine and vinorelbine have demonstrated
substantial activity in metastatic breast cancer. Finally, patients with
HER2-positive tumors receiving adjuvant trastuzumab might be
refractory (primary resistance) or might become resistant (secondary
resistance) to trastuzumab. The mechanisms of primary and secondary
trastuzumab resistance are not yet fully elucidated. Lapatinib, a new
target agent that simultaneously inhibits both HER-2 and EGFR
tyrosine kinases, has been shown to be active in trastuzumab-resistant
metastatic breast cancer. Moreover, several new agents targeting
HER-2 are currently under clinical development. There are no data on
rechallenge with trastuzumab in patients who had received this agent
as adjuvant treatment and relapsed after a long TFI, and this issue is a
new area of research.
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Bone metastases are part of a spectrum of conditions based on
dysregulated osseous metabolism. Metastatic cancer cells activate
osteoclasts, both directly, by producing and releasing local humoral
factors that result in osteoclast activation, and by activating osteo-
blasts, which in turn further affect osteoclast activity. Activated osteo-
clasts, when uncoupled and unbalanced from osteoblast activity, result
in net excess bone resorption, resulting in bone loss and eventually lytic
or mixed metastatic lesions. Therefore, the osteoclast, and the humoral
activation system that leads to osteoclast recruitment and activation
have become the major targets for developing therapies active in bone
metastases. Bisphosphonates are potent osteoclast inhibitors and
interfere with recruitment of osteoclast precursors, activation and
release of bone resorbing substances. Bisphosphonates represent the
treatment of choice for osteoporosis. They might also have weak, but
direct, antitumor effects. As single agents, bisphosphonates relieve
pain, and reduce the skeletal complication rate associated with bone
metastases. Prospective randomized trials have clearly demonstrated
that when added to standard antitumor therapy, bisphosphonates
reduce skeletal morbidity, fractures, pain and analgesic requirements,
as well as the need for radiotherapy or orthopedic interventions.
Bisphosphonates also increase the time to first skeletal event, thus
extending the complication-free survival of patients with bone
metastases. These observations have been made in a variety of tumor
types. The optimal duration of bisphosphonate therapy has not been
determined, and while the usual schedule of administration is monthly
intravenous therapy for this indication, there are ongoing trials
attempting to determine the most effective and safest schedule for
patients with bone metastases. Similar studies are ongoing for patients
with osteoporosis and osteopenia. Although bisphosphonates are very
well tolerated, the last few years have brought a number of anecdotal
reports of osteonecrosis of the jaw associated with bisphosphonate
administration. More recently, systematic retrospective analyses of
large databases have indicated a low but definite incidence of this
complication, predominantly in patients receiving third-generation,
potent bisphosphonates. These reports suggest the incidence to be in
the range of 0.1–2.0%, varying with tumor type and research methodo-
logy. There is insufficient information about prevention and manage-
ment of this condition, although risk factors include poor oral hygiene,
oral/dental interventions, increasing cumulative dose of bisphospho-
nates and duration of therapy.
There is much interest and ongoing trials to define the role of
bisphosphonates in the preventive treatment of primary breast cancer.
Whether bisphosphonates can prevent osseous metastases or not,
emerging information about their use in treatment-induced bone loss
might lead to the incorporation of these agents into the combined
modality management of primary breast cancer anyway. This makes the
determination of therapeutic benefit, optimal dose and schedule of
administration very important.
SYMPOSIUM IV
Primary Systemic Therapy and Adjuvant Treatment
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Breast cancer is an increasing global public health burden with more
than 1 million new cases anticipated worldwide and more than
200,000 new cases anticipated in the United States in 2007.
Screening and awareness have increased the detection of breast
cancer at its early stages where it is most curable, but many such
patients have microscopic metastatic disease even when diagnosed.
The outcome for such patients can only be improved through the
effective control of this undetected systemic disease, thus motivating
adjuvant therapy. For patients with sufficient risk, based historically on
nodal status, tumor size, specific histology, and hormone receptor
status, chemotherapy can be the only option or a component of
regimens including hormonal agents and anti-HER2 drugs. Genetic
profiling is a recent addition to our risk stratification methods and can
allow for more precise selection of chemotherapy. Historical
chemotherapy regimens were largely empiric combinations of drugs
with proven activity in advanced disease. More recent advances have
been translational, with preclinical development of the taxanes leading
to their testing in the adjuvant setting and mathematical modeling
leading to improvements in the delivery of otherwise standard agents.
Despite this mixture of empiricism and translational research, adjuvant
chemotherapy is highly effective, particularly in selected subsets of
patients, such as those with no expression of hormone receptors.
Building on the demonstration of activity for the humanized monoclonal
anti-HER2 antibody (trastuzumab) as adjuvant treatment, newer HER2
targeting drugs are in development and will be tested in this setting
(lapatinib). For the majority of tumors lacking overexpression of HER2,
planned research focuses on anti-angiogenic agents (bevacizumab).
For many patients, an optimized chemotherapy plan (that is, dose-
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dense administration of anthracyclines and taxanes) combined with
appropriate targeted agents is likely to offer even larger improvements
in outcomes than those already achieved.
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Adjuvant hormonal therapy for postmenopausal
women
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Approximately 75% of all breast cancer is hormone receptor positive
and the majority arises in postmenopausal women. In the United States
alone, there are over 100,000 women annually who are diagnosed with
postmenopausal hormone-receptor-positive disease. Adjuvant hormonal
therapy substantially decreases a woman’s risk of developing recurrent
breast cancer and improves overall mortality. For almost two decades,
a 5-year course of tamoxifen was the standard treatment offered to
almost all women with hormone-receptor-positive disease. Over the
past decade, the aromatase inhibitors have emerged as highly effective
agents in the treatment of hormone-receptor-positive breast cancer.
Multiple large trials including 25,000 women have assessed the role of
the aromatase inhibitors in the adjuvant setting. These studies have
demonstrated that the use of an aromatase inhibitor, either in place of
tamoxifen or following a 2-year to 5-year course of tamoxifen, will
reduce the risk of disease recurrence compared with the use of a
5-year course of tamoxifen alone. To date, these studies have not
demonstrated a substantial improvement in overall survival, but the
follow-up was relatively short. The optimal treatment approach has not
been identified. Recently completed and ongoing trials are comparing a
5-year course of an aromatase inhibitor with the use of sequential
therapy. Given the natural history of hormone-receptor-positive breast
cancer, there is also great interest in treatment strategies that extend
beyond 5 years. The toxicity profile of the aromatase inhibitors differs
from tamoxifen, and these differences need to be considered in making
clinical decisions. Ultimately, it is probable that different treatment
approaches will be appropriate for different women based on tumor
biology, pharmacogenetic variability, and susceptibility to side effects.
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Experiments on preclinical models have suggested that preoperative
introduction of chemotherapy of endocrine therapy can improve
survival by abrogating a postsurgical growth spurt and by addressing
micrometastatic disease at an earlier stage than when given post-
operatively. Clinical trials have not confirmed this hypothesis, although
they have demonstrated that preoperative systemic therapy reduced
the overall tumor burden, expanded the indications for breast-
conserving surgery to patients with more advanced disease, and
provided an in vivo assessment of response that facilitated the safe
and effective administration of systemic treatment. Preoperative
administration of systemic therapy also provides an improved
investigational model, since sequential monitoring with the primary
tumor in situ offers the opportunity for multiple biopsies to monitor the
biological effects of treatment. Large randomized trials have shown
preoperative chemotherapy to be at least equivalent in disease-free
and overall survival to the same chemotherapy administered
postoperatively. Emerging data suggest, however, that the effects of
systemic therapy in general, and preoperative therapy in particular, vary
with different subclasses of breast cancer (BC). The first such
observations were based on the estrogen receptor (ER). It is now
widely accepted that the magnitude of benefit from chemotherapy is
proportionately more modest for patients with ER+ tumors than for
ER– tumors. This is dramatically expressed in preoperative trials, where
the pathological complete remission (pCR) rate is fourfold to sixfold
higher for ER– BC than for ER+ BC. Similar variation in the pCR rate is
observed by grade. More recent reports have indicated that the pCR
rate was very low for invasive lobular cancers (almost always ER+)
compared with invasive ductal cancers. Paradoxically, although pCR
identifies a group of patients with improved survival compared with
patients who do not achieve pCR, patient groups with lower pCR rates
(those with ER+ tumors, those with low grade or lobular cancer) have
better overall survival than those who tend to have higher pCR rates.
This observation emphasizes the importance of understanding the
biological heterogeneity of BC, and parallels the observations made in
lymphoma over the past several decades: high-grade lymphomas
respond more readily to chemotherapy but have lower survival rates in
early follow-up than low-grade lymphomas. Studies based on gene
expression profiling in BC have confirmed the existence of at least
three distinct forms of BC: ER+/HER2–, HER2+, and ‘triple-negative’.
These three groups differ by much more than the individual gene (ER or
HER2) expression, and their clinical course and responsiveness to
different treatments is quite different too. Thus, HER2+ and triple-
negative tumors achieve a high pCR rate (40–50%) with standard
combinations, while ER+/HER2– tumors do not (pCR rate <10%).
There are other ramifications to drug sensitivity, and, most importantly,
gene profiling leads to the identification of potential new targets for
therapeutic intervention. Validation of such novel targets and
development of specific therapeutics might be the best legacy of
neoadjuvant treatment.
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Background Neoadjuvant endocrine therapy is being increasingly
used with two aims: to downstage cancers and reduce the need for
mastectomy; and to establish short-term clinical and/or biological
surrogate endpoints predicting for long-term outcome.
Methods The results of key randomised trials addressing these issues
are reviewed.
Results In the P24 trial for patients not suitable for conservative
surgery, neoadjuvant letrozole was shown to achieve a significantly
greater clinical overall response rate than tamoxifen (56% versus 36%,
P < 0.001) and a significantly better incidence of breast-conserving
surgery (45% versus 35%, P = 0.02). In the IMPACT trial, neoadjuvant
anastrozole was compared with tamoxifen and the combination (three
arms, equivalent to adjuvant ATAC). No significant difference in clinical
overall response was seen between the three arms although breast-
conserving surgery was considered feasibly significantly more often
with anastrozole (46%) than with tamoxifen (22%) or with the
combination (26%) (P = 0.03). In the PROACT trial, neoadjuvant
anastrozole achieved a higher clinical overall response rate than
tamoxifen (50% versus 40%) but this difference was not significant (in
the endocrine therapy alone group – excluding patients also treated
with chemotherapy). Breast-conserving surgery was achieved signifi-
cantly more often with anastrozole (43% versus 31%, P = 0.04).
The optimum duration of neoadjuvant endocrine therapy prior to
surgery has not been established but circumstantial evidence suggests
that it is at least 4 months, and probably longer.
In the P24 trial and the IMPACT trial, patients with higher levels of ER
expression had a significantly higher chance of clinical response.
Likewise in both trials, aromatase inhibitors appeared strikingly more




In the IMPACT trial, the change in proliferation rates after 2 weeks of
treatment as measured by Ki67 was significantly greater for
anastrozole than for tamoxifen or the combination, reflecting results in
the adjuvant ATAC trial, and suggesting that Ki67 might be a better
marker for long-term outcome than clinical response. Likewise, long-
term follow-up of the IMPACT trial showed that the absolute level of
Ki67 suppression after 2 weeks of neoadjuvant endocrine therapy
significantly correlated with long-term disease-free survival outcome,
and more so than baseline pre-treatment Ki67. Changes in expression
of > 2,800 genes were observed after 2 weeks of aromatase inhibitor
therapy.
Conclusion These results suggest that neoadjuvant endocrine therapy
is an effective clinical strategy to reduce the need for mastectomy in
postmenopausal women with large hormone receptor-positive breast
cancer. Short-term changes in molecular markers may be superior to
clinical response in predicting long-term outcome, and this hypothesis
is being further tested in a large prospective randomised trial.
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Many different cytotoxic agents are currently available for the treatment
of metastatic breast cancer (MBC), and multiple factors determine the
choice of treatment. These include previous adjuvant therapy, tumour
characteristics (for example, molecular receptors, sites of relapse),
patient characteristics (for example, performance status, age) and
patient preference.
The aims of treatment with chemotherapy for MBC are: to prolong
survival; to relieve symptoms; to improve and maintain quality of life;
and to delay disease progression.
Only a small minority of MBC chemotherapy trials has shown a
significant survival benefit, and to some extent this is explained by the
multiple lines of potential further therapy following completion of the
trial. Survival is therefore an uncertain endpoint in MBC trials.
Symptom improvement has been shown to correlate with response rate
in one trial but this important endpoint is not used often enough.
Quality-of-life endpoints are appropriate in principle, but in reality many
trials have shown a poor correlation with outcome, suggesting that this
tool may be relatively insensitive in this context. Time to disease
progression is a much used and important endpoint because it takes
into account the fact that symptom relief and prolonged survival relate
not just to patients achieving objective response, but also to those with
minor response or stable disease.
Specific issues relating to chemotherapy for MBC include the
following. There is evidence from older trials supporting the principle
that endocrine therapy should be used before chemotherapy in
patients with nonlife-threatening hormone-receptor-positive disease.
Patients whose primary is HER2-unknown should have this checked at
the time of relapse to determine whether trastuzumab should be given
in addition to chemotherapy. Ideally, patients with primary HER2-
negative disease should have metastatic disease rechecked since
there is evidence of HER2-positive conversion in up to 25% of such
patients. The choice of combination versus single-agent sequential
chemotherapy is a complex one. The weight of current evidence
suggests no significant survival difference with the combination, and
this may be associated with more toxicity. There is no absolute answer
here; choice depends on the nature of the drugs being used.
Multiple lines of chemotherapy are now available for MBC. Current
evidence suggests that it is only worth proceeding to third-line
treatment if there has been a response to first-line and/or second-line
therapy. New drug trials are appropriate for fit patients who have failed
two lines of conventional therapy, and sometimes earlier than this in
patients with nonlife-threatening disease.
SYMPOSIUM VI 
Targeted Therapy: Present and Future
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In breast cancer there is a global 40% loss of methylated cytosine, but
DNA hypermethylation indicates which genes are turned off in tumors
and tumor cell lines. Every tumor type has its own pattern of hyper-
methylation. Genes important in familial breast cancer are also
epigenetically silenced. In sporatic tumors, BRCA1 expression was
wiped out by a combination of loss of heterozygosity (gene deletion)
and epigenetic silencing (hypermethylation). In familial BRCA1 tumors,
hypermethylation occasionally serves as an alternate mechanism for the
‘second hit’, when there was not loss of heterozygosity. Other known
cancer genes are hypermethylated in breast cancers, such as those
that affect cell cycle (p16 INK4a), and hormone receptors (ER, PR).
New epigenomic approaches revealed the novel importance of
potential tumor suppressor genes, such as the prolactin receptor and
WRN, the Werner syndrome gene associated with premature aging
and increased cancer risk, which is silenced in a subset of breast
cancers. In addition to direct DNA hypermethylation, modification of
histones is another epigenetic mechanism with implications in breast
cancer. Overall, there is global loss of monomethylation and trimethy-
lation of histone H4 in cancer. New epigenetic drugs targeting DNA
methylation and histone deacetylation are in development for the
treatment of breast cancer.
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Vascular endothelial growth factor (VEGF), a potent angiogenic factor,
has been reported to be associated with a poor prognosis in primary
breast cancer and other solid tumours [1]. VEGF was observed to be one
of the most important mediators of tumour angiogenesis in human breast
cancer and was the only one linked to poor relapse-free survival [2].
VEGF affects tumour growth and metastasis in many forms of breast
cancer, including invasive/noninvasive, node-negative/node-positive,
inflammatory and metastatic disease. Also, VEGF expression has been
observed across a number of disease-related variables, including
hormonal and HER-2 status.
A complex relationship between oestrogen, the oestrogen-receptor
subtypes, and VEGF has been seen in preclinical breast cancer
models. Oestrogen modulates VEGF expression at the gene
transcriptional level [3]. VEGF expression in breast cancer cells
promotes oestrogen-independent tumour growth in ovariectomized
mice and VEGF-stimulated neovascularization, and contributed to
tumour growth in both oestrogen-treated and nonoestrogen-treated
mice. Tumour growth was highest in VEGF-expressing mice treated
with oestrogen [4].
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In multiple prospective and retrospective studies assessing blood and
tumour samples in lung cancer patients, VEGF and angiogenesis have
been associated with larger tumour size, increased rate of metastasis,
recurrence of disease and poorer overall and disease-free survival [5-7].
Bevacizumab is a humanized recombinant antibody that prevents
VEGF receptor binding, and inhibits angiogenesis and tumour growth.
In patients receiving an irinotecan plus fluorouracil/leucovorin regimen
for first-line treatment of metastatic colorectal cancer, the addition of
bevacizumab significantly increased overall survival. In the second-line
treatment of advanced colorectal cancer, patients who received
bevacizumab in combination with a fluorouracil/leucovorin plus
oxaliplatin (FOLFOX4) regimen had an overall survival time 2 months
longer than that in patients receiving FOLFOX4.
Bevacizumab has been tested in many tumours, proving efficacy when
added to almost any chemotherapy regimen. It has been hypothesized
that there are three main mechanisms by which bevacizumab exerts its
antitumour activity: regression of existing tumour microvasculature,
normalization of surviving mature tumour vasculature and inhibition of
vessel regrowth and neovascularization as an effect with continuous
treatment [8].
Based on preclinical findings that have shown the activity of
bevacizumab in breast cancer, bevacizumab monotherapy was tested
in a phase I/II dose escalation trial (AVF0776g) in metastatic breast
cancer (MBC) with three doses (3, 10 and 20 mg/kg every 2 weeks) in
75 patients who had relapsed following at least one conventional
chemotherapy regimen for metastatic disease. Combining data from
the three arms, the overall response (OR) rate was 6.7%, the median
duration of response (DR) was 5.6 months and overall survival (OS)
was 10.2 months. Bevacizumab was well tolerated although four
patients presented with headache with nausea and vomiting at the
higher dose (dose limiting toxicity). Comparison of data from the three
study arms indicated that a bevacizumab dose of 10 mg/kg every
2 weeks produced the best therapeutic ratio in this population of
heavily pretreated patients [9].
Bevacizumab has since been studied in several phase II trials with
different chemotherapy regimens (docetaxel, vinorelbine), targeted agents
(trastuzumab, erlotinib) and hormonal therapies (letrozol), showing
encouraging results and acceptable toxicity profiles in these combinations.
Nowadays, there is evidence for efficacy of bevacizumab from two
phase III trials (AVF2119g and E2100). The first phase III trial
published (AVF2119g) compared a combination of bevacizumab
(15 mg/kg every 3 weeks plus capecitabine 2,500 mg/m2 daily for
2 weeks of a 3-week cycle) versus capecitabine alone. A total of 462
women with MBC previously treated with an anthracycline and a taxane
were randomized to any of the study arms. The primary study endpoint
was progression-free survival (PFS) and secondary endpoints included
the OR rate, DR and OS. There was no significant difference in PFS
between the two arms. The proportion of progression-free patients at 6
months was 33.8% for the Xeloda-alone arm and 33.0% for the Xeloda
plus bevacizumab arm. Median PFS was 4.17 and 4.86 months,
respectively (HR = 0.98, P = 0.857). Overall survival data for the
Xeloda-alone arm (14.5 months) compared with the Xeloda plus
bevacizumab arm (15.1 months) was also not significant. Although the
addition of bevacizumab to capecitabine did improve PFS nor OS,
there was a significant increase in the OR rate in the capecitabine plus
bevacizumab arm compared with the capecitabine-only arm when the
data were analysed both by investigators (30.2% versus 19.1%;
P = 0.006) and by an independent review facility (19.8% versus 9.1%;
P = 0.001). However, no significant differences in PFS or in OS were
found between the two arms. The combination was found to be well
tolerated, with no increase in the frequency or severity of capecitabine-
related adverse events in the bevacizumab-containing arm [10]. In this
study, although the addition of bevacizumab to capecitabine did not
improve PFS (the primary endpoint), the OR rate doubled.
There have been a number of reasons hypothesized that could explain
these observations. First of all, it has been demonstrated that VEGF
inhibition is more effective in earlier disease, since in advanced disease
there are also other angiogenic factors that are overexpressed [11].
Another reason could be that patients were heavily pretreated, having
received both an anthracycline and a taxane prior to entering the trial.
The other phase III trial (E2100) is an ongoing open-label, phase III trial
in which bevacizumab is being evaluated in combination with weekly
paclitaxel as first-line therapy for MBC. Patients recruited to this trial
are less heavily pretreated than patients in AVF2119g. A total of 722
patients have been randomized to one of two arms: paclitaxel
90 mg/m2 alone every week for 3 weeks followed by 1 week without
treatment or paclitaxel plus bevacizumab 10 mg/kg every 2 weeks. No
crossover is permitted in this trial.
The objectives are to compare PFS, the OR rate and OS between the
arms. Preliminary results from the first preplanned interim analysis
showed a significant increase in median PFS in patients receiving
bevacizumab plus paclitaxel compared with paclitaxel alone (11.4
versus 6.11 months; P < 0.0001). This PFS result was obtained
following 89% of the required events. The OR rate for all patients was
29.9% (bevacizumab/paclitaxel) versus 13.8% (paclitaxel) (P < 0.0001),
and was 37.7% (bevacizumab/paclitaxel) versus 16% (paclitaxel)
(P < 0.0001) for patients with measurable disease only. The survival
data are still immature [12].
Differences in the patient populations may help to explain the
differences in results between the two phase III trials. Trial AVF2119
included a higher proportion of patients who had received chemo-
therapy, including those who had received both an anthracycline and a
taxane. A greater number of HER2-positive patients were also enrolled
in AVF2119, most of whom had previously received trastuzumab.
Trial AVF2119 patients were generally more heavily pretreated than
those enrolled in the E2100 trial. This may partly explain why the
significant response rate improvement seen in this trial did not translate
into a PFS benefit. Showing these results, it can be hypothesized that
bevacizumab should be used as early as possible to obtain the
maximum benefit.
There are many other ongoing phase III trials that are testing the use of
bevacizumab in combination with standard chemotherapy regimens.
The AVADO trial is an ongoing randomized, double-blind, placebo-
controlled, multicentre phase III trial that will randomize 705 patients to
receive docetaxel at a dose of 100 mg/m2 every 3 weeks with either
placebo, bevacizumab 7.5 mg/kg or bevacizumab 15 mg/kg. The
primary trial endpoint will be PFS. Secondary endpoints will include the
OR rate, duration of response, time to treatment failure, overall survival,
safety and quality of life. Another trial exploring bevacizumab in
combination with standard regimens is the RIBBON-1 study, a phase III
trial to be conducted in countries worldwide that will investigate further
combinations of bevacizumab and chemotherapy. The primary trial
endpoint is PFS. Investigators will assign patients to a chemotherapy
regimen, including specified regimens of anthracycline-based combina-
tion chemotherapy, taxane (docetaxel or Abraxane™) every 3 weeks, or
Xeloda. Patients are then randomized to receive bevacizumab
(15 mg/kg every 2 weeks) or placebo. Another combination that is also
being explored is bevacizumab plus trastuzumab. There is a strong
rational for combining both antibodies as the different factors that
bevacizumab and trastuzumab inhibit play important roles in tumour
growth and progression. It has been shown that activation of the HER
family of receptors induces VEGF expression and angiogenesis in
cancer cell models [13]. These observations suggest that combined
inhibition of VEGF and HER2 may enhance antitumour activity.
The feasibility of combining bevacizumab with trastuzumab was
evaluated in the phase I, open-label AVF2473s trial. A total of nine
patients with HER2-positive advanced or MBC were treated in one of
three cohorts. Data from this trial led to the recommendation of
bevacizumab 10 mg/kg every 2 weeks for use in combination with
trastuzumab 2 mg/kg weekly (after a loading dose of 4 mg/kg) in phase
II trials. The maximum tolerated dose was not reached. Analyses of
pharmacokinetic parameters showed that coadministration of
bevacizumab and trastuzumab does not alter the pharmacokinetics of
either agent, indicating no interaction between the two agents. The
combination was well tolerated, with no grade 3/4 adverse events [14].
Recently presented at the San Antonio Breast Cancer Symposium
2006 have been the first efficacy data from an ongoing,
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nonrandomized, open-label, uncontrolled, phase II study trial
(TORI-B-03) that explores the combination of bevacizumab plus
trastuzumab for the first-line treatment of Her2-positive locally
recurrent, surgically unresectable, or metastatic breast cancer. The
interim data of 37 patients showed that the combination of both
targeted agents induces an overall response rate of 54% with an
acceptable safety profile without inducing the typical chemotherapy-
related side effects.
There is currently running a phase III trial of bevacizumab, docetaxel
and trastuzumab (AVEREL) in patients with previously untreated,
HER2-positive MBC: 320 patients will be randomized to receive either
docetaxel and trastuzumab or docetaxel, trastuzumab and bevacizumab
until disease progression. Patients from the control arm will not be
permitted to crossover to receive bevacizumab upon progression. The
primary trial endpoint is PFS. Other endpoints include response rate,
duration of response, OS and safety.
There is also evidence from phase II trials proving the efficacy of
adding bevacizumab to other agents such as vinorelbine, erlotinib or
letrozol. All this combinations have demonstrated encouraging results
with acceptable toxicity profiles that warrant further exploration.
Besides the use of bevacizumab in the metastatic setting, it has been
hypothesized that the greater benefit could be obtained when used in
earlier stages. The progression of breast cancer is accompanied by the
production of a wide array of proangiogenic growth factors that
promote and support tumour growth. When tumours are small they
secrete VEGF, which acts as a paracrine factor to induce endothelial
cell proliferation and blood vessel formation, mediating tumour
progression. As the tumour develops further, additional factors are also
secreted [15]. This evidence suggests that the inhibition of VEGF may
be more beneficial in earlier stages, as neoadjuvant or adjuvant
treatment. There are many trials, planned and ongoing, exploring
bevacizumab in the neoadjuvant setting. An ongoing, phase II trial of
bevacizumab in combination with docetaxel in the neoadjuvant setting
(AVF2307s) is being conducted in patients with locally unresectable
breast cancer with or without metastasis. Patients receive bevacizumab
10 mg/kg every 2 weeks and docetaxel 35 mg/m2 weekly for the first
6 weeks of an 8-week cycle. After two cycles, patients with stable
disease or response, undergo surgery and radiotherapy, followed by
further chemotherapy (not containing bevacizumab). The study
objectives are to evaluate the efficacy and safety of neoadjuvant
bevacizumab with docetaxel in breast cancer patients. Preliminary
efficacy data showed that bevacizumab plus docetaxel reduces tumour
vascular permeability and microvessel density [16]. Combined
response data for both study arms revealed seven complete responses
(14.3%), 32 partial responses (65.3%), five patients with stable
disease and a further five with progressive disease. This gave an OR
rate of 79.6%, with no difference between the study arms. Both PFS
and OS were 40 months in the docetaxel arm and neither had been
reached in the docetaxel plus bevacizumab arm [17]. TORI-B-02 is a
phase II neoadjuvant trial currently being conducted at the University of
California, Los Angeles. A total of 90 patients are being enrolled into
four different treatment arms, in order to compare two different
bevacizumab doses with placebo: Arm 1: bevacizumab 7.5 mg/kg,
followed by six cycles of bevacizumab 7.5 mg/kg in combination with
TAC (docetaxel, doxorubicin and cyclophosphamide) every 3 weeks;
Arm 2: placebo 7.5 mg/kg, followed by six cycles of placebo 7.5 mg/kg
in combination with TAC every 3 weeks; Arm 3: bevacizumab
15 mg/kg, followed by six cycles of bevacizumab 15 mg/kg in
combination with TAC every 3 weeks; and Arm 4: placebo 15 mg/kg,
followed by six cycles of placebo 15 mg/kg in combination with TAC
every 3 weeks. Then, 28–42 days after receiving chemotherapy, patients
eligible for surgery will undergo resection. After either receiving surgery
or completing chemotherapy, patients in Arms 1 and 3 will receive
bevacizumab at their previous dose until disease progression. Patients
in Arms 2 and 4 will not receive further therapy before disease progres-
sion. The primary objectives of the TORI-B-02 trial are to evaluate the
safety and toxicity of bevacizumab given as preoperative therapy to
patients with stage II/III breast cancer in combination with the TAC
regimen. Analysis of changes in HIF-1α levels will also be carried out,
in order to compare tumour angiogenesis in patients given
bevacizumab and placebo.
Other trial objectives include investigation of the clinical benefit of
adding bevacizumab to TAC in the neoadjuvant setting. Parameters to
be evaluated are the clinical objective response rate (complete
response plus partial response), pathologic complete response rate
and rate of breast-conserving surgery. As wound-healing complications
have previously been reported in bevacizumab clinical trials, the effect
of bevacizumab on postsurgical wound-healing will also be investigated
as well as the rate of cardiac heart failure.
The most successful use of antiangiogenic therapy has been predicted
to be in the adjuvant treatment, and there is a clear biologic basis and
rationale for exploring bevacizumab in this clinical setting. A large
proportion of patients with breast cancer have been reported to have
primary tumours that overexpress VEGF, and overexpression of VEGF
is associated with increased rates of relapse [18]. The trials planned
with bevacizumab in the adjuvant setting will confirm the efficacy of
adding an antiangiogenic therapy to standard combinations.
The data from the trials currently ongoing will tell us the efficacy of
combining bevacizumab with other drugs used in the metastatic
setting, besides docetaxel or capecitabine, the exact role of
bevacizumab in neoadjuvant and adjuvant settings, and perhaps it will
be possible to identify which patients are most likely to benefit from
VEGF-targeted therapies.
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Novel strategies for HER-2-positive metastatic
disease: mechanisms and therapeutic options to
overcome trastuzumab resistance
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The HER2 tyrosine kinase receptor is overexpressed in approximately
25% of invasive breast cancers, and has been associated with a poor
prognosis [1]. Trastuzumab (Herceptin) and lapatinib (Tykerb) are the
two therapies currently approved by the FDA for the treatment of HER2-
overexpressing metastatic breast cancer. The majority of patients that
initially respond to trastuzumab monoclonal antibody-based therapy
develop progressive disease within 1 year of treatment initiation [2].
Preclinical studies have indicated several molecular mechanisms that
may contribute to the development of trastuzumab resistance [3].
Increased signaling via the phosphatidylinositol 3-kinase/protein kinase
B (or Akt) pathway could contribute to trastuzumab resistance due to
activation of multiple receptor pathways. These include HER2-related
receptors or non-HER receptors such as the insulin-like growth factor-I
receptor, which appears to cross-talk to HER2 in resistant cells [4].
Additionally, loss of function of the tumor suppressor PTEN, the
negative regulator of Akt, results in heightened Akt signaling that leads
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to decreased sensitivity to trastuzumab [5]. Decreased interaction
between trastuzumab and its target receptor HER2, due to steric
hindrance of the HER2 receptor by cell surface proteins, such as MUC-
4 [6], or by the presence of a truncated HER2 protein [7], may block
inhibitory actions of trastuzumab. Novel therapies targeted against these
aberrant molecular pathways are being studied in laboratory and clinical
settings, and offer hope that the efficacy and duration of response to
trastuzumab can be greatly improved.
Lapatinib (Tykerb) is a small molecule tyrosine kinase inhibitor that
targets EGFR and HER-2 [8]. Clinical responses were observed in
patients with HER2-overexpressing metastatic breast cancer [9]. A
recent phase III randomized trial showed that a combination of lapatinib
and capecitabine (Xeloda) was superior to capecitabine alone [10],
leading to the FDA approval of lapatinib in 2007. Clinical trials are
ongoing to determine the role of lapatinib in the frontline setting for
metastatic breast cancer in combination with trastuzumab and taxanes,
as well as in the neoadjuvant and adjuvant settings.
Other novel strategies being tested in patients with HER2-over-
expressing breast cancer include monoclonal antibodies targeting HER-
2 on different epitopes than trastuzumab (for example, pertuzumab),
attaching toxins to trastuzumab (for example, trastuzumab-DM1), Hsp90
inhibitors that degrade the HER-2 protein (for example, 17-AAG),
irreversible small molecule tyrosine kinase inhibitors (for example, HKI-
272), agents directed against IGF-IR and multitarget kinase inhibitors.
Indirect approaches include immunotherapy and anti-angiogenic
therapy. Clinical trials are evaluating the safety and efficacy of targeted
biologic therapies, both as single agents and in combination with other
biologics and in combination with standard chemotherapy and
endocrine therapy. One of the main challenges is to match the right
patient with the right drug(s) at the right time.
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Prognostic factors for the node-negative breast
cancers
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Objective The proportion of node-negative breast cancer patients has
been increasing with improvement of diagnostic modalities and early
detection. However, there is a 20–30% recurrence in node-negative
breast cancer. To identify the prognostic factors for node-negative
breast cancers, we studied the impact of many clinico-pathologic para-
meters on the outcome of the node-negative breast cancer patients.
Methods The data of 1,110 node-negative breast cancer patients who
underwent curative surgery at the Severance Hospital, Yonsei
University College of Medicine, were reviewed. The impact of many
clinico-pathological parameters on the outcome was investigated.
Univariate survival curves for disease-free survival and death were
estimated using the Kaplan–Meier method: group differences in
survival time were tested by the log-rank test. Multivariate Cox regres-
sion analysis was performed to compare and identify independent
prognostic factors.
Results The mean age was 47.2 years. The median follow-up was
88 months. Recurrence occurred in 161 patients; 64 patients with
locoregional recurrences, 129 with systemic recurrences, and 32 with
both. The 5-year overall survival rate was 93.3%. The rate of
locoregional recurrence for a 10-year period was significantly lower in
the mastectomy group compared with those in the breast conservation
therapy group (94.7% versus 79.6%, P = 0.000). No other prognostic
factors except age affected locoregional recurrence. There was less
systemic recurrence in patients with age greater than 35, with
histologic grade I, and with intraductal components greater than 20%.
Thus, the 10-year distant relapse-free survival rates were 87.4% versus
79.8% (P = 0.039), 93.5% versus 85.5% (P = 0.024), and 94.4%
versus 82.0% (P = 0.007), respectively. There was no statistical
significance in the other prognostic factors that influence systemic
recurrence.
Conclusion Patient age, histologic grade, and presence of intraductal
component were identified as independent prognostic factors in node-
negative breast cancer patients.
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Retreatment with trastuzumab in Her2-positive
metastatic breast cancer patients: a clinical study
F Carabantes-Ocón, E Saez-Lara, L Burgos-Garcia, 
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Objective To study the benefit of trastuzumab in monotherapy or
combined with different chemotherapeutic agents in the treatment for




Patients and methods The clinical evolution of patients with Her2+
MBC diagnosed by IHC3+/FISH+, and treated with trastuzumab in
several lines for the metastatic disease, has been studied retro-
spectively.
Results Twenty-four patients with Her2+ MBC were treated with
several regimens containing trastuzumab alone or associated with
chemotherapy and/or hormonotherapy. In the first line of treatment 12
RR (50%), 11 SD (45%), with a 95% clinical benefit, was observed.
The patients received a second line obtaining 8 RR (33%), 15 SD
(62%), with a clinical benefit of 95%. Seventeen patients were treated
with a third line, 5 RR (29.4%) and 11 SD (64%) being observed, with
a clinical benefit of 93%. Seven patients received a fourth line. In these,
2 RR and 4 SD, with a clinical benefit of 85%, were observed. Fifteen
of the patients, with RE+, received hormonotherapy plus trastuzumab
alone or with chemotherapy in one or more lines of treatment, obtaining
8 RR (53%) and 4 SD (26%), with a clinical benefit of 79%.
Conclusion The association of herceptin with chemotherapy and/or
hormonotherapy demonstrates a very active treatment in patients with
Her2+ MBC. The benefit seems to continue in patients who already have
received treatment with trastuzumab even in more than one regimen.
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Do breast cancer tumours downsize as well as
downgrade with neoadjuvant chemotherapy?
M Dani1, J McDonnell1, S Karp2, V Jaffe1
1Department of Surgery (Breast Firm) and 2Department of Oncology,
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Objective Neoadjuvant chemotherapy (NC) is increasingly being used
for large primary breast carcinomas with the aim of improving breast-
conservation surgery (BCS) rates. This study was conducted to assess
the tumour response following NC.
Methods In this retrospective study over a 4-year period, 61 women
with large operable invasive breast cancers (T2–4 N0–2 M0), unsuitable
for BCS, were consecutively treated with NC (5-FU, epirubicin,
cyclophosphamide and Taxotere). Pathological response was
monitored, comparing original core biopsy histology with final
excisional histology.
Results The mean age of patients was 48.6 years (range 30–70). Of
the 61 patients, BCS was achieved in 48 (79%) patients. On the core
biopsy, four (6.5%) patients had grade I cancer, 26 (43%) had grade II
cancer and 31 (51%) had grade III cancer. Final histology showed no
invasive cancer in eight (13%) patients (seven DCIS, and complete
pathological response in one patient). In the rest of the patients, four
(6.5%) had grade I tumours, 26 (43%) had grade II tumours and 23
(38%) had grade III tumours. Overall, 14 patients (23%) showed a
decrease in histological grade (see Table 1). Seven patients (11.5%)
had a higher grade than the initial core.
Conclusion In our series of patients receiving NC for breast cancer,
there is not only a significant downsizing (permitting BCS) but also a
trend of downgrading of the tumour, and this is seen particularly in
poorly differentiated tumours. The higher grade on final histology
compared with the core could be due to an unrepresentative core
biopsy in large tumours prior to NC.
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Saline instillation into the cavity after conservation
surgery for breast cancer is a safe way of improving
cosmesis
M Dani, T Tahmid, J McDonnell, V Jaffe
Department of Surgery (Breast Firm), Chase Farm Hospital, London,
UK
Breast Cancer Research 2007, 9(Suppl 1):P4 (doi: 10.1186/bcr1710)
Objective To demonstrate that saline instillation is a safe and simple
procedure for volume replacement after wide local excision in breast
surgery.
Methods We performed a pilot study over a 12-month period at the
Chase Breast Unit. One hundred and six patients who underwent wide
local excision for breast cancer had saline instilled into the surgical
cavity at the time of wound closure. This was to maintain the volume
and shape of the breast after removal of significant amounts of tissue.
We measured the volume instilled and monitored the wound and
breast postoperatively at 1 week, 2 weeks and 3 months. As is our
normal practice, all patients received perioperative antibiotics.
Results The volume of fluid instilled varied between 30 and 180 ml.
The weight of tissue removed was in the range of 12–116 g. The fluid
was retained within the cavity. However, in one case the wide local
excision cavity unexpectedly communicated with the axillary clearance
cavity and all the fluid was evacuated spontaneously through the
axillary suction drain with a resultant visible reduction in the volume of
the breast. There were no complications of saline instillation. In
particular, there was no early or late infection in any of the 106 patients.
None of the patients reported any additional discomfort or pain. There
were no visible abnormalities apart from a subjective enhancement in
the shape and volume of the breast. This improvement in shape and
volume was maintained for the entire length of assessment (3 months).
Conclusion Saline instillation is a simple and safe method of replacing
volume after removal of significant amounts of breast tissue.
Surprisingly, the benefits seem to persist. We are now proceeding to
fully evaluate this technique in a formal prospective trial.
P5
A safety and efficacy study of bleomycin sulfate and
electroporation in patients with metastatic or locally
recurrent breast cancer
V Paramanov1, O Tyurin1, S Polenkov2, PM Goldfarb3
1Cherkassy Regional Oncologic Clinic, Cherkassy, Ukraine; 2Chernigiv
Regional Oncology Centre, Chernigiv, Ukraine; 3Consulting Medical
Director, Inovio Biomedical Corporation, San Diego, CA, USA
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Objective The study evaluated bleomycin sulfate (BS) followed by
electroporation (EP) treatment in patients with recurrent in-breast or
chest-wall tumors. EP treatment following intralesional injection of BS
has been studied in various cancers, and significantly increased
destruction of cancer cells within the treatment field. The treatment has
also been used as an intracellular delivery system for gene therapies
and DNA vaccines.
Methods Patients with histologically confirmed recurrent breast cancer
following partial or complete mastectomy received BS intratumorally,
1 unit/cm3 tumor volume, followed by EP under general anesthesia. A
CE-marked medical device (MedPulser®) and a six-needle array
applicator were used to electroporate each tumor. Safety evaluations
and monitoring for local tumor recurrence were performed periodically
up to 24 weeks.
Results Ten female patients with 11 tumors were enrolled. The mean
age was 58.0 years (range 43.6–67.7). The mean tumor volume was
1.81 cm3 (0.01–6.60), the mean BS dose was 1.80 U (range 0.50–5.08),
and the mean number of EP applications was 11 (range 7–16). No
treatment-related serious adverse event was observed. Nonserious
adverse events were unremarkable during the 30-day follow-up period.
At 24 weeks, the complete response rate was 75% (6/8) among
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Initial histology 
(core) Final histology designation (post NC)
No residual 
Grade n invasive cancer DCIS Grade I Grade II Grade III
III 28 1 5 1 4 17
II 29 0 2 1 21 5
I 4 0 0 2 1 1
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patients with evaluations for treated lesions; two patients were
inevaluable for tumor response.
Conclusion Treatment with this drug–device combination was well
tolerated in these patients, a majority of whom were free of local
disease at 24 weeks. These results suggest a promising potential for
BS/EP as a new treatment for controlling local disease in patients with
recurrent breast cancer.
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Predictive value of HER2 expression for the selection
of adjuvant chemotherapy in breast cancer patients
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Objective To determine the predictive value of HER2 expression for
the selection of adjuvant chemotherapy (antracycline or nonantra-
cycline based) in patients with breast cancer.
Methods Medical records of primary breast cancer patients treated at
the Oncology Center of Latvia from January 2002 to August 2005
were retrospectively reviewed. One hundred and ninety-two patients
with histopathologically confirmed breast cancer, who had undergone
radical surgery and adjuvant chemotherapy (CT), were identified. Tumor
characteristics were: ER+ in 62.5%, ER– in 37.5%, HER2-positive (3+
by IHC) in 30.2% (58 patients), HER2-negative (0, 1+) in 54.7% (105
patients); patients with score 2+ (15.1%, 29 patients) were excluded
from analysis. Staging: I (20.8%), II (51%), III (29.2%); 43.8% patients
were node negative, 56.2% were node positive. Median age at
diagnosis was 52.4 (30–75) years.
Results Antracycline-based CT (FAC or FEC) was received by 62.9%
patients in the HER2-negative group and 41.4% in the HER2-positive
group, nonantracycline based (CMF) CT in 37.1% and 58.6% respec-
tively. The median follow-up time was 21.3 (6.3–51.7) months. A total
of 25.2% tumor recurrences were observed. Median time to relapse
was 12.5 (1.4–34) months. In the HER2-positive group the relapse
rate was 20.8% in patients receiving antracycline-based CT versus
29.4% in patients receiving nonantracycline-based CT (P = 0.09). In
the HER2-negative group the relapse rate was 33.3% in patients
receiving antracycline-based CT versus 15.8% in patients receiving
nonantracycline-based CT (P = 0.2). The subgroup of patients with
HER2-negative, ER-negative tumors had the worst prognosis (relapse
rate 45%) regardless of the CT received.
Conclusion In patients with HER2 overexpression, antracycline-based
CT produced a significantly lower relapse rate when compared with
nonantracycline-based CT. In HER2-negative patients there was no
benefit from antracycline-based CT compared with nonantracycline-
based CT. However, a longer follow-up period is needed to confirm the
results.
P7
Axillary study before surgery in patients with breast
cancer
M Izquierdo, R Fabregas, J Feu, L Lopez Marin, B Navarro, 
C Ara, M Cusido, F Tresserra
Institut Universitari Dexeus, Barcelona, Spain
Breast Cancer Research 2007, 9(Suppl 1):P7 (doi: 10.1186/bcr1713)
Objective Axillary study with ultrasound and cytological puncture with
fine-needle aspirate (FNA) in patients with invasive breast cancer is a
diagnostic method included in protocols.
Methods We studied 159 patients with invasive breast cancer with
axillary ultrasound and cytological puncture with fine needle of
suspicious nodes before surgery. Suspicious nodes were those with at
least one of the following signs: long to short axis ratio less than 1.5,
absence of hilius and cortical disruption. If the results were compatible
with metastasis, then we performed axillary lymphadenectomy; if it was
found to be benign, then we conducted sentinel node biopsy.
Results In 54 patients (33.96%) FNA was positive. When we
conducted axillary lymphadenectomy, 13 patients (24%) were found to
have one positive node, seven patients (13%) two positive nodes, nine
patients (16%) three positive nodes, and 25 patients (45%) more than
three positive nodes.
Conclusion Axillary study with ultrasound and FNA before surgery
allows exclusion of a group of patients from sentinel node biopsy.
P8
Resveratrol downregulates acetyl-CoA carboxylase
alpha and fatty acid synthase by activating
AMP-activated protein kinase and suppressing the
mammalian target of rapamycin signal pathway
S Yoon, B-W Park, K-S Kim
Yonsei University College of Medicine, Seoul, Korea
Breast Cancer Research 2007, 9(Suppl 1):P8 (doi: 10.1186/bcr1714)
Expression of HER2 is reported to be increased in approximately 30%
of human breast carcinoma. Fatty acid synthase (FASN) was expressed
higher in HER2-overexpressing breast cancer cells. Resveratrol (3,5,4′-
trihydroxystilbene), a red-wine-derived polyphenol, has been shown to
suppress cancer cell proliferation, and to interfere with the several
signaling pathways and induce apoptosis. We investigated the effects
of resveratrol on the expression of lipogenic enzymes in BT-474 cells,
in which HER2 overexpresses cells. Resveratrol treatment to BT-474
cells resulted in inhibition of acetyl-CoA carboxylase alpha (ACCalpha)
and FASN expression and a strong activation of AMP-activated protein
kinase (AMPK), which could be mimicked by the changes caused by
AICAR treatment or forced expression of constitutively active AMPK
mutant. The decreased ACCalpha and FASN expressions by
resveratrol were abolished by overexpression of dominant-negative
AMPK mutant. The activation of AMPK was accompanied with the
reduction of the mammalian target of rapamycin (mTOR), which plays a
key role in the upregulation of ACCalpha and FASN expression in
BT-474 cells. These results indicate that downregulation of HER2-
mediated ACCalpha and FASN expression by resveratrol is regulated
through suppressing the mTOR signaling pathway resulting from the
activation of AMPK in breast cancer cells.
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Partial breast irradiation with an electron beam for
patients submitted to conservative surgery
MAC Maia, MM Netto, MS Maciel, JC Donoso, JV Salvajoli, 
ACA Pellizzon, RC Fogaroli, KW Bocalletti, C Tanous
Hospital AC Camargo, São Paulo – SP, Brazil
Breast Cancer Research 2007, 9(Suppl 1):P9 (doi: 10.1186/bcr1715)
Objective To evaluate the feasibility, acute complications and cosmetic
results of partial breast cancer radiotherapy in initial tumors, with an
electron beam, in patients submitted to conservative surgery and
sentinel lymph-node dissection.
Methods From 2005 to 2007 we evaluated 40 patients, median age
63 years, with T1–T2 (maximum 3 cm) breast cancer, clinically N0
axilla, submitted to conservative surgery and intraoperative radiotherapy
with an electron beam.
Results Of 40 patients, we had 73% T1 and 27% T2; 82% N0, 8%
N1micro, and 10% N1. As for acute complications we had 2%
infection and 5% fat necrosis. Regarding cosmetic results, 85% were
good and excellent, 10% were fair and 5% were bad.
Conclusion This is a quite feasible method for partial breast irradiation,
with satisfactory results in terms of acute complications and cosmetic
results. For local control and late complications we still have to wait
longer and wait for the reports of the open trials. It also should be





Positive axillary lymph node metastases in T1–T3
breast cancer: prognostic value of extracapsular
extension
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Breast Cancer Research 2007, 9(Suppl 1):P10 (doi: 10.1186/bcr1716)
Background Extracapsular extension (ECE) of axillary metastases has
importance as a risk factor for local or distant recurrence. Poorer
survival in breast cancer has been suggested, but its prognostic value
has not been uniformly confirmed.
Methods From January 2000 to March 2007, 356 breast cancer
patients were operated on in the Department of General Surgery of
General Hospital ‘Sveti Vracevi’ in Bijeljina. We selected 173 (48.6%)
cases with pT1–pT3 node-positive breast cancer. The prognostic
significance of ECE of axillary metastases was evaluated with respect
to disease-free survival, overall survival, and the patterns of disease
recurrence. Such prognostic significance was then compared with that
of other clinical and pathologic factors.
Results Ninety-five patients (26.68%) presented with ECE. Thirty
patients (31.57%) were identified as having three or less lymph nodes
involved, 26 patients (27.36%) patients four to six nodes, 18 patients
(18.9%) seven to nine nodes, and 22.16% patients 10 or more nodes,
respectively. With a median follow-up of 86 months, factors with
independent prognostic value for disease-free survival by multivariate
analysis included absence of estrogen receptors (P < 0.005), pN
category (P < 0.01), presence of lymphovascular invasion (LVI;
P < 0.005), and ECE (P < 0.001). An independent negative prognostic
effect on overall survival was observed for absence of estrogen and
progesterone receptors (P < 0.05), pN category (P < 0.05), and
presence of LVI (P < 0.005) and ECE (P < 0.001).
Conclusion ECE demonstrated a stronger statistical significance in
predicting prognosis than the pN category and was also related to an
increased risk of distant recurrences. We suggest that the decision on
adjuvant therapy should consider the presence of ECE of axillary
metastases and peritumoral LVI as indicators of high biological
aggressiveness. Balancing the risks and benefits of irradiation, we
continue to recommend that complete axillary irradiation is not routinely
indicated after adequate axillary dissection.
P11
Study of the combination gemcitabine and
trastuzumab in the treatment of HER2+ metastatic
breast cancer
S Menjón-Beltrán, R Olivencia-Dueso, E González-Jiménez, 
MJ Titos
Unidad de Ginecología Oncológica, Hospital Universitario Virgen de
las Nieves, Granada, Spain
Breast Cancer Research 2007, 9(Suppl 1):P11 (doi: 10.1186/bcr1717)
Objective Trastuzumab and gemcitabine are two active drugs for meta-
static breast cancer (MBC) treatment. We conducted a retrospective
study of this combination in patients with Her2+ MBC in our hospital.
Patients and methods Retrospective assessment of the efficacy of
trastuzumab and gemcitabine association in patients with MBC
previously treated with different lines of chemotherapy.
Results Seventeen heavily pretreated patients with poor prognosis
were evaluated. Fourteen patients (82%) had received prior adjuvant
chemotherapy and 11 patients (64%) prior adjuvant radiotherapy; 12
patients (70%) had received prior chemotherapy for MBC. All the
patients had received taxanes and 15 (88%) had received anthra-
cyclines also. We observed a 41% rate of response, two complete
responses, five partial responses, and 41% stable disease, obtaining
82% clinical benefit. The time-to-progression was 7.2 months. Median
survival has not yet been reached. Nine of the patients had received
previous treatment with trastuzumab alone or in combination, four
additional responses and four stable disease responses being
observed, which produces an 88% clinical benefit. One patient
discontinued treatment because of LVEF decline (> 50%).
Conclusion Trastuzumab and gemcitabine constitutes a well-tolerated
and very active regimen for Her2+ MBC heavily pretreated patients,
including patients who have been previously treated with trastuzumab.
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Clinical role of trastuzumab in metastatic breast
cancer: experience of a center
S Menjón-Beltrán, R Olivencia, E Gonzalez
Unidad de Ginecología Oncológica, Hospital Universitario Virgen de
las Nieves, Granada, Spain
Breast Cancer Research 2007, 9(Suppl 1):P12 (doi: 10.1186/bcr1718)
Objective To study the efficacy of different regimens of treatment
based on trastuzumab in patients with Her2+ metastatic breast cancer
(MBC).
Patients and methods Medical records of 47 Her2+ MBC patients
were retrospectively studied in our center between December 1999
and February 2004. The Her2 status was determined by immuno-
histochemistry (Herceptest), FISH being used to discriminate the
doubtful cases.
Results Forty-seven patients with MBC of bad prognosis treated
previously have been evaluated, a complete response (CR) being
observed in 30% of the cases with a response rate (RR) (CR + partial
response (PR)) of 63%. The stable disease rate (SD) was 12%, which
provides a clinical benefit (CR + RP + SD) of 75%. Thirteen of these
patients received a new scheme of treatment based on trastuzumab
after progression to the first regimen containing trastuzumab, 76% of
RR (CR + PR) and 30% of CR being observed. Three of these patients
received a third regimen of treatment with trastuzumab, still obtaining
one CR (RR 33%), and one SD.
Conclusion The association of trastuzumab with chemotherapy
constitutes a very active regimen in previously treated patients with
MBC of poor prognosis. This activity even continues in patients who
have already received a previous treatment based on trastuzumab.
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BRCA1a has antitumor activity in triple-negative
breast cancers
C Yuli, N Shao, G Oprea-llies, J Okoli, ESP Reddy, VN Rao
Cancer Biology Program, Department OB/GYN, Morehouse School of
Medicine, Atlanta, GA, USA
Breast Cancer Research 2007, 9(Suppl 1):P13 (doi: 10.1186/bcr1719)
Most BRCA1-related breast cancers are high-grade, basal-like,
estrogen receptor (ER)-negative, progesterone receptor (PR)-negative,
and Her2-negative. Triple-negative breast cancers are more common in
younger black women than their white counterparts, have higher rates
of distant metastasis, and currently there are no effective treatments
against these cancers. We have previously characterized a splice
variant of BRCA1 (BRCA1a/p110), which is expressed at reduced
levels in several breast tumors. Stable expression of BRCA1a resulted
in inhibition of growth in vitro of human breast, ovarian, prostate and
colon cancer cells, and only those cells with wild-type Rb were
sensitive to BRCA1a-induced growth suppression and the status of
p53 did not affect the ability of BRCA1a to suppress growth of tumor
cells. We have introduced BRCA1a into the CAL51 cell line, which is
negative for ER and PR, and our results using semiquantitative
immunocytochemistry show CAL51 to be negative for HER2. These
transfectants were analyzed for BRCA1a protein expression by
western blot analysis. The BRCA1a transfectants were slow growing
and 98% inhibited in their growth in soft agar. BRCA1a also
significantly inhibited CAL-51 triple-negative breast cancer xenografts
in nude mice. These results suggest that the majority of exon 11
sequences lost in BRCA1a are not required for the tumor suppressor
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function. This is the first report showing antitumor activity of BRCA1a
in triple-negative breast cancers.
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Diagnosis of familial breast cancer by multiplex PCR
and clinical parameters
H Rassi
National Medical Academy of Post-Graduate Education, Kiev, Ukraine
Breast Cancer Research 2007, 9(Suppl 1):P14 (doi: 10.1186/bcr1720)
Objective Mutation analysis of mtDNA and nDNA are helpful in the
determination of developmental potential, early diagnosis and gene
therapy for breast cancer. In our study, we optimized the multiplex PCR
in AFPBT and compared the results with morphological and immuno-
histochemical parameters for detection of BRCA mutations and
mtDNA4977 deletion in familial and nonfamilial breast cancers.
Methods The multiplex PCR was conducted on DNA from 71 archive
breast tissue samples and 13 blood samples. We compared different
paraffin removal procedures and DNA extraction procedures in
combination in order to optimize and compare the results of the
multiplex PCR with morphological and immunohistochemical para-
meters for diagnosis of breast cancers.
Results The highest proportion of successful gene amplifications was
obtained with a DNA isolation procedure using proteinase K digestion
with followed boiling. Three 5382insC mutations were identified from
16 archival familial patients (19%) and five mtDNA4977 deletions were
detected from nine blood familial breast cancers by the multiplex PCR.
The mtDNA4977 deletion was highly prevalent in peripheral blood
(56%), but it was absent in the breast tissue of cancer cases.
Furthermore, familial breast cancer tumors exhibited higher mitotic
activity, higher polymorphism, lower necrosis, lower tubules, higher ER-
negatives and PR-negatives and lower TP53-positives than nonfamilial
cancers.
Conclusion Our results demonstrate that DNA extracted by the simple
boiling method with a microwave yielded higher proportions of
successful gene amplifications than the DNA extraction kit.
Furthermore, differences in successful gene amplification may be
related to the size and number of the gene fragments amplified. Our
analysis shows that testing of mtDNA4977 deletions and 5382insC in
combination with morphological and immunohistochemical parameters
may be an extremely effective and inexpensive tool in testing breast
cancer patients aimed to identify individuals with high risk of familial
breast cancers.
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Novel method of sentinel lymph node detection in
malignant tumors using preparation ‘UNIMAG’
B Surguladze, R Zhorzoliani, T Tskitishvili
“Magnetic Fluids in Medicine and Biology”, ATT Ltd, Georgia, USA
Breast Cancer Research 2007, 9(Suppl 1):P15 (doi: 10.1186/bcr1721)
Preparation ‘UNIMAG’ is registered by the pharmacological committee
of Georgia (Cert.: DA Nr-000142, 08.04.2005; Author – PhD, ScD,
Professor Besiki Surguladze; Owner – ‘ATT’ Ltd, Sci. Laboratory
‘Magnetic fluids in Medicine and Biology’). Preparation ‘UNIMAG’
represents a magnet-sensitive stabile suspension of magnetite nano-
particles (magnetic fluid). After the peritumoral injection of ‘UNIMAG’,
magnetite nanoparticles will be absorbed by macrophages, which
deliver them through the lymphatic capillaries to regional lymph nodes.
This mechanism of magnetite nanoparticle transport underlies the new
method of sentinel lymph node detection. Diversely to the other
dyestuff agents used in this direction, magnetite nanoparticles actively
filled lymphatic nodes and colored them in bold black. This significantly
facilitates the atraumatic separation of lymph nodes during lymph-
adenectomy. Besides the intraoperative indication of lymphatic nodes,
‘UNIMAG’ provides the possibility of X-ray and ultrasound imaging of
sentinel lymph nodes and performing their biopsy in the preoperative
period. This assuredly helps in a better planning of the operation and
considerably improves its radicalism. Even in the case of ideal surgical
intervention it is impossible to remove all the microscopic lymphatic
vessels and nodes that could be damaged by the tumor micro-
metastasis. In the field of high-frequency electromagnetic waves, the
magnetite nanoparticles give us possibilities of local, distance
hyperthermia on micrometastatic lesions. This minimizes the potentiality
of development of postoperative recurrence and secondary metastatic
processes.
P16
Frequency of febrile neutropenia in patients treated
with taxane/epirubicine and colony-stimulating
growth factors for breast cancer: comparison of
filgrastim/lenograstim with pegfilgrastim
W Schippinger, R Holub, N Dandachi, T Bauernhofer
Hellmut Samonigg Medical University Graz, Department of Internal
Medicine, Division of Medical Oncology, Graz, Austria
Breast Cancer Research 2007, 9(Suppl 1):P16 (doi: 10.1186/bcr1722)
Objective This report describes a single centre’s experience on the
efficacy of pegfilgrastim compared with filgrastim or lenograstim in
reducing the incidence of febrile neutropenia in patients receiving
combination chemotherapy with docetaxel or paclitaxel and epirubicin
in neoadjuvant and adjuvant settings.
Methods A total of 118 patients with breast cancer were treated with
either epirubicin 75 mg/m2 and docetaxel 75 mg/m2 or with epirubicin
90 mg/m2 and paclitaxel 200 mg/m2 every 3 weeks; 88 patients
received G-CSF support with daily filgrastim or lenograstim and 30
patients with pegfilgrastim once per cycle.
Results Eight (9.1%) patients with prophylactic filgrastim or leno-
grastim support developed febrile neutropenia, and one (3.3%) patient
in the pegfilgrastim group (P = 0.445). Febrile neutropenia occurred in
13 (2.7%) of 476 filgrastim or lenograstim supported chemotherapy
cycles, and in two (1.2%) of 172 cycles with pegfilgrastim support
(P = 0.376). The frequency of chemotherapy delays and dose reduc-
tions was not significantly different between the two G-CSF treatment
groups.
Conclusion The results of this study demonstrate a trend towards
superiority of pegfilgrastim over filgrastim or lenograstim in reducing
the frequency of febrile neutropenia in patients treated with taxane and
epirubicin chemotherapy regimens for breast cancer.
P17
Comparison of side-effect profiles during active
treatment versus follow-up in the International
Breast Cancer Intervention Study I tamoxifen
prevention trial
I Sestak1, R Edwards1, A Howell2, J Cuzick1
1Cancer Research UK, Centre for Epidemiology, Mathematics and
Statistics, London, UK; 2Department of Surgical Oncology, Newcastle
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Breast Cancer Research 2007, 9(Suppl 1):P17 (doi: 10.1186/bcr1723)
Objective Tamoxifen is an effective drug but its role in prevention is
limited by its side-effect profile, particularly related to endometrial
problems and thrombotic events. We present updated results on the
comparison of side effects between active treatment and the follow-up
period incorporating four additional years of follow-up.
Methods In the International Breast Cancer Intervention Study I (IBIS-I)
study, 7,154 women at increased risk of breast cancer were either
randomised to tamoxifen 20 mg/day or placebo for 5 years. Women
gave detailed information of any side effects at each 6-monthly follow-
up visit and once a year after active treatment.
Results During active treatment, large numbers of side effects were
reported by participants in both treatment arms. However, the only
major categories that showed differences were vasomotor and
gynaecological side effects, which were about 12% higher in the
tamoxifen group than the placebo group. Thromboembolic events were
significantly higher in the tamoxifen group compared with the placebo
Available online http://breast-cancer-research.com/supplements/9/S1
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group (85 versus 42, P < 0.001), whereas myocardial infarctions were
reduced in women on tamoxifen during active treatment (2 versus 7,
P = 0.09). Women on tamoxifen developed significantly more endo-
metrial cancer during active treatment than women on placebo (12
versus 3, P = 0.02). After active treatment, most menopausal-like side
effects decreased and the differences between the two treatment arms
were not significant. Reports on vaginal discharge decreased after
stopping tamoxifen. Thromboembolic events were similar between the
two treatment arms after active treatment (32 versus 26, P = 0.4). No
significant difference in endometrial cancer between the two treatment
groups was found during follow-up time (8 versus 5, P = 0.4).
Conclusion Although large numbers of side effects were reported,
tamoxifen was well tolerated and no new safety concerns were
identified. For most side effects no significant difference between
treatment groups was found after ceasing tamoxifen.
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Minimal residue disease (MRD)
A Zaidi1, G Tripuraneni1, S Weller2, B Ward2, HD Sinnett3, 
RC Coombes1, MJ Slade1
1Department of Oncology, Imperial College, London UK, 2Department
of Medical Oncology and 3Department of Surgery, Charing Cross
Hospital, London UK
Breast Cancer Research 2007, 9(Suppl 1):P18 (doi: 10.1186/bcr1724)
Introduction: We developed a quantitative PCR (QPCR) technique for
the detection of cytokeratin 19 (CK19) transcripts in blood and bone
marrow and compared this with immunocytochemistry (ICC). The aim
was to monitor these assays for micrometastases in primary breast
cancer patients.
Materials and methods Bone marrow (BM) aspirates were taken
2–4 years following chemotherapy from 39 patients who had entered a
trial comparing high-dose chemotherapy (n = 17) with standard
chemotherapy (n = 22). The BM was tested for the presence of CK19-
positive cells using ICC and QPCR. We compared this with 20 low-
risk (T1N0) patients.
Results See Table 1. A total of 232 aspirates were analysed from the
high-risk patients and 100 from the T1N0 patients. The number of
patients positive was therefore approximately the same irrespective of
therapy in the high-risk patients, and the levels of positivity were not
significantly different (PCR, P = 0.078; and ICC, P = 0.253). The levels
of positivity, however, were higher in the high-risk patients than in the
low-risk patients.
Conclusion We have demonstrated that: (a) patients who received
high-dose and standard chemotherapy showed similar results, (b)
patients with a low-risk of relapse had markedly lower values as
compared with high-risk primary breast cancer patients, and (c)
micrometastases persist in a substantial proportion of patients.
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Algorithm for identification of individuals with
hereditary predisposition to breast cancer and other
breast cancer-associated forms of malignant
neoplasms
IV Zalutsky, NN Antonenkova, GM Porubova
NN Alexandrov Research Institute of Oncology and Medical Radiology,
Minsk, Belarus
Breast Cancer Research 2007, 9(Suppl 1):P19 (doi: 10.1186/bcr1725)
Introduction Hereditary cancers make up 5–15% of all forms of breast
cancer (BC). BRCA1/2 mutations determine about 50% of hereditary
BC forms and other pathologic BRCA1/2 genotype-associated forms
of malignant neoplasms. Meta-analysis has demonstrated a high
probability for development of ovarian cancer, gastric cancer, colon
cancer, endometrial cancer, pancreatic cancer, skin melanoma, urinary
bladder cancer, and head and neck tumours with pathologic BRCA1/2
genotype, which should be taken into consideration in medicogenetic
consulting and monitoring of patient carriers.
Objective To develop and introduce into clinical practice a diagnostic
algorithm targeted at active identification of hereditary BC and other
BRCA1/2 mutation-associated forms of malignant neoplasms.
Methods Questionnaires for patients, and molecular genetic blood
analysis.
Results Questionnaires for patients with BC, ovarian cancer or colon
cancer reveal individuals with cancer-burdened heredity, whose blood
is analysed for the presence of germinal mutations. Relatives of
BRCA1/2 mutation-positive patients are subject to examination for
both germinal mutation-carrying and tumour markers. A cohort is
formed for targeted prophylactic medical examinations.
Conclusion (1) An original method is developed for active identifica-
tion of hereditary BC and other BC-associated malignant neoplasms.
(2) The proposed method makes it possible to conduct targeted and
efficient prophylatic medical examinations of germinal mutation carriers.
P20
Identification of individuals with hereditary
predisposition to breast cancer and other breast
cancer-associated forms of malignant neoplasms:
data of the Belarusian Cancer Registry
IV Zalutsky, NN Antonenkova
NN Alexandrov Research Institute of Oncology and Medical Radiology,
Minsk, Belarus
Breast Cancer Research 2007, 9(Suppl 1):P20 (doi: 10.1186/bcr1726)
Introduction Nowadays, all developed countries spend enormous
resources on breast cancer (BC) treatment. However, no significant
reduction in the population’s BC rates due to the improvement of
treatment methods can be expected in the near future.
Objective To use the data of the Belarusian Cancer Registry (BCR) for
active identification of individuals with hereditary predisposition to BC
and other BC-associated forms of malignant neoplasms.
Materials and methods To make the analysis, 4,442 patients with
second primaries (SP), one of which was BC, were selected, as well as
BC patients with disease origination before age 40. There were 7,137
such patients.
Results BC was most commonly associated with skin cancer (24.9%),
endometrial cancer (11.8%), ovarian cancer (9%), gastric cancer
(7.8%), cervical cancer (5.9%), rectum cancer (5.2%), thyroid cancer
(5%), colon cancer (4.8%), renal cancer (3.6%), lung cancer (3.4%),
skin melanoma (2.3%) and other cancers (16.3%). The fate of each
patient was retraced.
Conclusions (1) BCR data enable one to identify individuals potentially
predisposed to hereditary BC and other BC-associated forms of
malignancies, according to two features. (2) Using the risk factors for
Breast Cancer Research    Vol 9 Suppl 1 VII Madrid Breast Cancer Conference
Table 1 (abstract P18)
Incidence of positivity
Standard High-dose 
chemotherapy chemotherapy All high risk T1N0 
(n = 22) (n = 17) (n = 39) (n = 20)
QPCR 58/138 (42%) 41/94 (44%) 103/238 (43%) 26/100 (26%)
ICC 50/110 (45%) 37/80 (46%) 90/198 (45%) 27/96 (28%)
Both 34/110 (34%) 26/80 (32%) 44/198 (22%) 14/96 (15%)
Either 73/138 (53%) 42/94 (45%) 127/238 (53%) 39/100 (39%)
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development of hereditary BC and other BC-associated forms of
malignant neoplasms makes it possible to draw the relatives of the
identified individuals into genetic consulting. (3) The rates of BC
association with other forms of malignancies in SP patients were
evaluated in the Belarusian population. (4) The use of BCR data and
active involvement of relatives of persons with a cancer burden in
oncogenetic consulting offer opportunities for early diagnosis and
prevention of hereditary BC and other BC-associated forms of
malignant neoplasms.
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Tachosil® to reduce the morbidity of axillary lymph
node dissection in breast cancer
E Barranger, O Morel, G Akerman, C Malartic, D Clement
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Breast Cancer Research 2007, 9(Suppl 1):P21 (doi: 10.1186/bcr1727)
Background Seroma formation after axillary lymph node dissection in
breast cancer remains a problem despite many efforts to reduce
surgery-related morbidity. The aim of the present study was to evaluate
the impact of a fibrin-glue-coated collagen patch (Tachosil®; Nycomed
Laboratory, Denmark) to reduce the volume and duration of post-
operative axillary drainage, the duration of hospital stay, and procedural
safety.
Patients and methods Twenty-five patients with breast cancer were
included in this prospective study. All patients underwent breast
surgery including lumpectomy or mastectomy followed by axillary lymph
node dissection (Berg Level I and II). In 13 patients, a surgical haemo-
stasis sponge Tachosil® was applied from the apex axillae to the
thoracic longus nerve and 12 had standard closure of the axillary
lymphadenectomy area. Patients did not differ with respect to general
characteristics, such as age, body mass index, treatment modality, and
tumor stage distribution. There were six mastectomy and five
lumpectomy operations in the Tachosil® group, and seven mastectomy
and four lumpectomy surgeries in the control group. The mean number
of removed lymph nodes was 11.9 in the Tachosil® group with a mean
of 1.2 metastatics nodes, and was 12.2 in the control group with a
mean of 2.5 metastatic nodes.
Results The mean duration of axillary drainage was 3.3 days in the
Tachosil® group and 5.5 days in the control group. The mean total
drainage volume was 246 ml in the Tachosil® group and 470 ml in the
standard closure group. The mean length of postoperative hospital stay
was 3.5 days in the Tachosil® group and 5.5 days in the standard
closure group. Seroma formation after drain removal was found in four
patients with a mean of drainage volume of 161 ml in the Tachosil®
group, and in five patients with a mean of drainage volume of 517 ml in
the standard closure group. No intolerance of the product was
described.
Conclusion The use of Tachosil® in the axillary area in patients with
breast cancer requiring axillary dissection seems to reduce the volume
and duration of postoperative axillary drainage, the duration of hospital
stay, and the frequency and volume of seroma after axillary drainage.
Larger series are required to confirm these results.
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imaging for sentinel lymph node biopsy in breast
cancer
E Barranger1, K Kerrou2, S Pitre3, MA Duval3, C Coutant1, 
R Siebert3, J Talbot2, Y Charon3, S Uzan1
1Gynécologie Obstétrique, Hôpital Lariboisière, Hôpital Tenon AP-HP,
Paris, France; 2Médecine Nucléaire, Hôpital Tenon AP-HP, Paris,
France; 3Laboratoire IMNC–CNRS Paris 7–Paris 11, Orsay, France
Breast Cancer Research 2007, 9(Suppl 1):P22 (doi: 10.1186/bcr1728)
Background The growing interest in the sentinel lymph node (SLN)
detection concept has led to the development of several prototypes of
hand-held gamma cameras. After the first successful clinical trials with
intraoperative imaging probes, the time has come to quantify the
clinical benefit of these devices.
Objective To compare the hand-held camera (POCI) with a
lymphoscintigraphy in order to precisely localize SLNs in patients with
breast cancer requiring SLN biopsy.
Methods The SLN protocol consisted of a peritumoral injection of
160 MBq 99mTc-labeled nano-colloids performed 2 hours before the
lymphoscintigraphy, which is realized preoperatively using a conven-
tional single-head gamma camera and then the hand-held POCI
camera (field-of-view, 13 cm2) (Figure 1). The day after, in the operating
room, the patients undergo one blue-dye subcutaneous tumoral
injection. Before incision the surgeon first uses the POCI to perform an
intraoperative lymphoscintigraphy and then the counting probe
(Europrobe CsI, Eurorad) for transcutaneous SLN prelocalizations. The
POCI camera was slowly moved on the skin until SLN identification.
The axillary area was scanned with the POCI camera with 10-second
acquisition images. SLN detection was defined as positive on the basis
of a local radioactivity increase in the intraoperative images of the
surveyed region. The SLN excision biopsy was guided, following the
established procedure, using the counting probe and blue dye. Finally,
a complementary scanning procedure was performed with the POCI
directly in the operative wound before skin closure to confirm complete
excision or to detect some residuals SLNs. The number and the
localization of SLNs obtained by both intraoperative detectors are
compared with those obtained the day before with the conventional
gamma camera.
Results To date, 33 patients (mean age: 64 years) have been included
in this clinical protocol. A SLN was identified by lymphoscintigraphy in
31/33 patients (94%), versus 30/33 (90.9%) with the POCI (P > 0.3).
The mean number of SLNs identified by lymphoscintigraphy was 1.6
(range: 0–4), versus 1.8 (range: 0–4) with the POCI (Table 1). The day
of the surgery, at least one SLN (mean: 1.9; range: 0–4) was identified
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Table 1 (abstract P22)
Results of SLN identification with lymphoscintigraphy and POCI
Total SLNs Mean 95% CI Range
Preoperative lymphoscintigraphy 54 1.6 1.28–1.99 0–4
POCI camera the day before surgery 59 1.8 1.46–2.12 0–4
POCI intraoperative imager 61 1.9 1.55–2.15 0–4
Figure 1 (abstract P22)
Preoperative image by POCI showing two hot sentinel nodes.
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by the POCI in 32/33 patients (97%) (P = 0.13). At least one SLN
(mean: 2.3; range: 1–4) was identified in all patients during the surgery.
Concerning the duration of these procedures, the mean acquisition
time was 15 minutes (range: 10–30) with lymphoscintigraphy,
8.8 minutes (range: 3–18) with the POCI used the day before surgery
and 3.35 minutes (range: 2–6.5) with preoperative POCI.
Conclusion These preliminary clinical results show that the POCI
camera is able to predict the number and localization of breast cancer
SLNs. The POCI camera appears to be a promising tool to complete or
replace the preoperative standard lymphoscintigraphy, especially in
surgical centers without an onsite nuclear medicine department.
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Introduction and objective Lapatinib (L) is a tyrosine kinase inhibitor
of EGFR and HER2. The inhibition of these two pathways can affect
tumor growth by reducing the EGFR-dependent proliferative stimulus,
by restoring apoptosis, and possibly by enhancing sensitivity to
chemotherapy (CT). On these premises, the combination of L with CT
or with CT and trastuzumab (T) is promising. We have therefore
designed a phase II randomized trial to evaluate the activity and safety
of this combination as preoperative therapy for HER2+ operable breast
cancer (BC). The primary endpoint was percentage of pathologic
complete response (pCR). Secondary aims were the breast objective
response, breast conservative surgery, safety, molecular responses,
and gene expression related to pCR.
Patients and methods After a core biopsy for diagnosis, biomarker
evaluation and storage of fresh tissue for molecular analyses, patients
with HER2+ stage II–IIIA BC are randomized to: arm A, CT + T; arm B,
CT + L; arm C, CT + T + L. CT consists of: paclitaxel 80 mg/m2 weekly
for 12 weeks, followed by four courses of FEC (5-FU 600 mg/m2 +
epirubicin 75 mg/m2 + cyclophosphamide 600 mg/m2 i.v.) every
3 weeks. T is administered at the dose of 2 mg/kg weekly in arms A
and C; L is administered at 1,500 mg p.o. daily in arm B, and at
1,000 mg p.o. daily in arm C. Both T and L are administered throughout
the duration of CT. The following biomarkers are evaluated at baseline,
and at surgery: EGFR, HER2, pTEN, pAKT, pMAPK, apoptosis (TUNEL
Test), Ki67.
Sample size Assuming a 50% increase in the pCR rate for the CT + T +
L arm versus CT + T or CT + L, 52 patients will be enrolled in the first
stage; in case we observe 13 pCR, an additional 68 patients will be
enrolled, for a total of 120 patients (Simon’s design).
Results Twelve patients have so far been randomized. Preliminary
safety data will be presented at the meeting.
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Finding bone metastases is frequently important for clinical decisions
affecting quality of life. Detection of such bone metastatic lesions
allows radiation therapy or surgical interventions to prevent pathologic
fractures from disabling the patients. We investigated 53 breast cancer
patients referred by surgeons, radiotherapists and chemotherapists.
Adsorption of 99mTc-MDP occurs in the mineral phase of the bone.
High-sensitivity bone scanning in determining the presence and extent
of metastatic disease is an extremely important tool in decision-making.
Bone scans demonstrate metastatic lesions much earlier than X-ray,
CT or MRI. 99mTc-MDP 22–25 mCi was injected i.v. In total, 53
patients were investigated. On visual analysis there were positive scan
findings (bone mets) in 17 patients (33.4%) and negative scan findings
(normal bone scan) in 34 patients (66.6%). Significance of bone mets
in the management of disease occurs when clinically stage I and
scintigraphically stage IV; here a change of treatment is needed.
Sensitivity for detecting bone mets is quoted as 95% or above. Bone
scintigraphy is a noninvasive technique used for detection of breast
cancer bone metastasis. Quality of life will be good if diagnosed early
and accurately and if managed properly.
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